TWI573576B - Absorbent items - Google Patents

Description

Absorbent article

The present invention relates to absorbent articles.

In the case of absorbent articles, such as sanitary napkins, pads, etc., the basic performance improvement is achieved through long-term accumulation of technology development. Compared with before, after absorbing excretions such as menstrual blood, there is little leakage, etc. Further, in pursuit of high functionality, for example, it has a feeling of similarity to underwear, and even if excretion of menstrual blood or the like is absorbed, the top sheet is still dry, and even after absorbing high-viscosity menstrual blood, there is no stickiness, and the top sheet is dry. Moreover, the user is also eager to have a sense of trust in the absorbent article. For example, when the absorbent article is replaced, it can be seen that the absorbent article does absorb menstrual blood.

For example, Patent Document 1 discloses that the absorption of cellulose-based hydrophilic fibers containing one or two or more kinds of surfactants selected from the group consisting of a sugar alkyl ether and a sugar fatty acid ester is contained in a portion other than the skin contact surface. article.

Further, Patent Document 2 discloses that an emulsion composition containing a polypropylene glycol material is disposed on an inner surface (a surface on the garment side) of the top sheet, an inner surface (a surface on the body side) of the back sheet, an inner surface of the top sheet, and An absorbent article such as a substrate between the inner surfaces of the back sheets.

Further, Patent Document 3 discloses an absorbent article in which an emulsion composition containing a polypropylene glycol material is used on the outer surface (surface on the body side) of the top sheet.

[Previous Technical Literature] [Patent Literature]

[Patent Document 1] Japanese Patent Laid-Open No. 2008-029830

[Patent Document 2] Special Table 2010-518918

[Patent Document 3] Special Table 2011-510801

However, in the invention described in Patent Document 1, it is attempted to use a surfactant to change the viscosity and surface tension of high-viscosity menstrual blood, thereby accelerating the absorption rate of the liquid, but the effect is insufficient, and after absorbing high-viscosity menstrual blood, Achieve no stickiness and a dry feel on the top sheet. Further, in the invention described in Patent Document 1, the effect of the surfactant tends to cause the menstrual blood to spread to the top sheet, and after the menstrual blood is absorbed, the surface of the top sheet is likely to be red. Therefore, the absorbent article described in Patent Document 1 is not designed to allow the user to see menstrual blood absorption.

Further, in the inventions described in Patent Documents 2 and 3, the inventors of the present invention have confirmed that the polypropylene glycol material has different absorption capacities due to its molecular weight, and in the low molecular weight polypropylene glycol material, the top sheet remains sticky after absorption of blood. The tendency to red blood that is prone to residual blood. Therefore, the absorbent articles described in Patent Documents 2 and 3 absorb menstrual blood, but can be visually recognized by a non-user.

Therefore, the present invention has an object of providing an absorbent article which can absorb the menstrual blood by visually recognizing the absorbent article and retaining the menstrual blood inside the absorbent body by the wearer.

The present inventors have found an absorbent article comprising a liquid-permeable top sheet, an absorbent body, a liquid-impermeable back sheet, and a second sheet between the top sheet and the absorbent body, which is characterized by a liquid dripping test. In the above [1], the liquid remaining ratio of the top sheet and the second sheet is 3.0% by mass or less, and [2] the liquid diffusion length in the longitudinal direction of the absorbent article of the skin contact surface of the top sheet is higher than that of the absorbent body. The above-mentioned problem can be solved by an absorbent article having a short liquid diffusion length in the longitudinal direction of the absorbent article on the side of the garment.

When the absorbent article of the present invention is exchanged, since it is possible to visually confirm that the absorbent article absorbs menstrual blood and the menstrual blood remains inside the absorbent body, the user can feel a sense of security.

[Best Mode for Carrying Out the Invention]

The absorbent article of the present invention will be described in detail below.

[absorbent article]

The absorbent article of the present invention has the following characteristics in the liquid dripping test.

[1] The liquid residual ratio of the top sheet and the second sheet is about 3.0% by mass or less.

[2] The liquid diffusion length in the longitudinal direction of the absorbent article of the skin contact surface of the top sheet is shorter than the liquid diffusion length in the longitudinal direction of the absorbent article on the garment side of the absorbent body.

The inventors have conducted various reviews and found that the less red blood (liquid residual rate) remaining on the surface of the top sheet during the replacement of the sanitary napkin, and the spread of menstrual blood spread over the skin contact surface of the top sheet is longer than the back. The spread of menstrual blood spread over the garment side of the sheet is short, and the performance of the absorbent article is recognized, and the feeling of relief to the absorbent article tends to be obtained.

That is to say, the user is psychologically aware that the residual liquid of the menstrual blood on the skin contact surface of the top sheet is less, and the diffusion of menstrual blood on the skin contact surface of the top sheet is longer than that of the side of the back sheet. The spread of menstrual blood is long, and the more it is judged that the menstrual blood discharged from the skin is away from the skin, and it is a good product that does not burden the skin.

In the present specification, the "liquid dropping test" is carried out in the following order.

(1) The tip end of the pipette was placed at the center of the absorbent article at a height of 10 mm, and a pipette having a front end inner diameter of 1.2 mm was fixed.

(2) The pipette was filled with 1.0 g of horse EDTA blood at 37 ± 1 °C.

(3) preliminarily measuring the mass of the top sheet, the second sheet, and the absorbent body, and sequentially absorbing the absorbent body, the second sheet, and the top sheet together with a clip or the like to form an absorbent article such that the center of the absorbent article is Set the way directly below the pipette. Also, a back sheet can be placed under the absorbent body.

(4) Horse EDTA blood was dropped by a pipette at a rate of 100 g/min.

In the case of the liquid residual ratio, after (4), the following operations were carried out.

(5) After dropping for 1 minute, separating the materials and measuring the quality of each material, the liquid residual ratio is expressed by the following formula: liquid residual ratio (% by mass) = 100 × (quality of the material after the test (g) - quality of the original material (g)) / 1.0 (g)

Calculated.

The measurement was carried out 5 times, and the average value thereof was used.

The following operations were carried out after (4) in terms of the liquid diffusion length.

(5') After dropping for 1 minute, the diffusion of menstrual blood on the skin contact surface of the top sheet and the garment side of the absorbent body was measured using both the ruler in the longitudinal direction of the absorbent article and the width direction in the vertical direction. Sex.

(6) The measurement was carried out 5 times, and the average value thereof was used.

In the present specification, the "skin contact surface of the top sheet" refers to the surface of the top sheet that is in contact with the skin of the wearer, and then the "surface of the garment side of the absorbent body" refers to the side of the garment on the side of the absorbent body. That is, the side of the back sheet side.

The above test was carried out in a thermostatic chamber at 20 °C.

Further, the center of the absorbent article refers to the center in the longitudinal direction and the center in the width direction.

In order to prevent coagulation, the horse EDTA blood system is added with horse blood of ethylenediaminetetraacetic acid.

The liquid residual ratio of the top sheet and the second sheet is about 3.0 mass % or less, preferably 2.5% by mass or less, more preferably about 2.0% by mass or less, still more preferably about 1.5% by mass or less, and most preferably about 1.2% by mass or less.

For example, the low residual liquid of the top sheet means that the top sheet is less bloody, most of the blood moves to the second sheet and/or the absorber, and the top sheet and the second sheet have a lower liquid residual rate, which means the top sheet. And the second sheet is less bloody, and most of the blood moves to the absorber.

In the absorbent article of the present invention, the liquid remaining ratio of both the top sheet and the second sheet is in the above range, and even if body pressure is applied during use, the menstrual flow can be reduced, so that there is no stickiness and dryness can be obtained. sense. Further, when the used absorbent article is replaced, the menstrual blood is hardly left on the skin contact surface of the top sheet, and the wearer can feel at ease.

The liquid diffusion length in the longitudinal direction of the absorbent article of the skin contact surface of the top sheet is preferably about 90% or less, more preferably about 80% or less, in the longitudinal direction of the absorbent article on the garment side of the absorbent body. It is preferably about 70% or less, and then about 60% or less.

When the liquid diffusion length in the longitudinal direction of the absorbent article of the present invention is within the above range, the absorbed menstrual blood can be seen and retained in the portion away from the skin, that is, the absorbent body, so that a feeling of relief can be obtained.

For the same reason, the liquid diffusion length in the width direction of the absorbent article of the skin contact surface of the top sheet is preferably shorter than the liquid diffusion length in the width direction of the absorbent article on the garment side of the absorbent body, and the skin of the top sheet is preferred. The liquid diffusion length in the width direction of the absorbent article of the contact surface is preferably about 90% or less, more preferably about 80% or less, still more preferably about 70% or less, and further preferably about 60% of the surface on the garment side of the absorbent body. The best of the following.

In the case of measuring the liquid diffusion length in the longitudinal direction of the absorbent article, the liquid diffusion length was measured as follows.

(1) In the horse EDTA blood diffusion region, the foremost end portion (end portion 1) and the last end portion (end portion 2) are marked.

(2) The length in the longitudinal direction of the absorbent article between the end portion 1 and the end portion 2 is measured.

Further, when there is no distinction between the horse EDTA blood diffusion region and the plural, the length of the absorbent article between the two end portions in the longitudinal direction is measured.

Further, when the liquid diffusion length in the width direction of the absorbent article is measured, the liquid diffusion length can be measured as follows.

(1) In the equine EDTA blood diffusion region, the rightmost end portion (end portion 1) and the leftmost end portion (end portion 2) are marked.

(2) The length in the width direction of the absorbent article between the end portion 1 and the end portion 2 is measured.

Further, the length of the absorbent article in the two apical portions in the width direction is measured regardless of whether the horse EDTA blood diffusion region is divided into one case and divided into plural numbers.

As a means for achieving the specific liquid residual ratio and the specific liquid diffusion length of the absorbent article, for example, the top sheet and the second sheet may have an IOB of about 0.00 to 0.60, a melting point of about 45 ° C or less, and 25 100 g of water is a blood modifying agent having a water solubility of about 0.00 to about 0.05 g and a weight average molecular weight of less than 1,000. Hereinafter, the blood modifying agent will be described in detail.

[blood modifier]

IOB (Inorganic Organic Balance) is an indicator of the balance between hydrophilicity and lipophilicity. In this specification, it refers to the formula by Oda: IOB = inorganic value / organic value

The calculated value.

The inorganic value and the organic value are based on the organic concept map described in the field of "The prediction and organic concept map of organic compounds" by Fujita Mu, Vol. 11, No. 10 (1957) p. 719-725.

The organic and inorganic values of the main base of Fujita are summarized in Table 1 below.

For example, in the case of an ester of a carbon number 14 tetradecanoic acid and a carbon number 12 dodecyl alcohol, the organic value is 520 (CH ₂ , 20 × 26), and the inorganic value is 60 (-COOR, 60). ×1), and IOB=0.12.

In the above blood modifying agent, IOB is preferably from about 0.00 to about 0.60, preferably from about 0.00 to about 0.50, more preferably from about 0.00 to about 0.40, still more preferably from about 0.00 to about 0.30. The lower the IOB, the higher the organicity and the higher affinity with the blood cells.

In the present specification, the "melting point" refers to the peak top temperature of the endothermic peak when the solid shape changes to a liquid state when measured at a temperature increase rate of 10 ° C /min in a differential scanning calorimeter. The melting point can be measured by using a DSC-60 DSC measuring apparatus manufactured by Shimadzu Corporation, at a temperature increase rate of 10 ° C /min.

The above blood modifying agent may have a liquid or solid at room temperature if it has a melting point of about 45 ° C or lower, that is, the melting point may have a melting point of about 25 ° C or higher, or about 25 ° C or less, followed by, for example, about -5 ° C. Melting point of -20 ° C, etc. The melting point of the above blood modifying agent is about 45 ° C or lower, as will be described later.

The above blood modifying agent has no lower limit at its melting point, but preferably has a lower vapor pressure. The vapor pressure of the blood modifying agent is preferably from about 0 to about 200 Pa at 25 ° C (1 atm), more preferably from about 0 to about 100 Pa, more preferably from about 0 to about 10 Pa, still more preferably from about 0 to about 1 Pa. It is then particularly good from about 0.0 to about 0.1 Pa.

When the absorbent article of the present invention is used in contact with a human body, the vapor pressure is preferably from about 0 to about 700 Pa at 40 ° C (1 atm), more preferably from about 0 to about 100 Pa, and further preferably from about 0 to about 10 Pa. Preferably, it is from about 0 to about 1 Pa, more preferably from about 0.0 to about 0.1 Pa. When the vapor pressure is high, there is a problem that the vaporization during storage, the amount of the blood modifying agent is reduced, and the odor is generated during use.

Further, the melting point of the blood modifying agent can be used in accordance with the weather, the length of time used, and the like. For example, in an area where the average temperature is below 10 ° C, by using a blood modifying agent having a melting point of about 10 ° C or lower, the blood modifying agent can stably reform the blood even after the menstrual blood is excreted and cooled by the ambient temperature. .

Further, when the absorbent article is used for a long period of time, the melting point of the blood modifying agent is preferably higher than the range of about 45 ° C or lower. The blood modifying agent does not easily move even when it is used for a long period of time due to the influence of sweating and friction during use.

The solubility of 0.00~0.05g of water is 25°C, and after adding 0.05g of the sample in 100g of deionized water, it is allowed to stand for 24 hours. After 24 hours, it can be judged by the dissolution of the sample by gently stirring it.

Further, in the present specification, the "solubility" of the water solubility includes a case where the sample is completely dissolved in deionized water to form a homogeneous mixture, and the sample is completely emulsified. Also, "completely" means a mass that has no sample in deionized water.

In this technical field, the surface of the top sheet is coated with a surfactant for the purpose of changing the surface tension of the blood or the like and rapidly absorbing the blood. However, since the surfactant generally has high water solubility, the top sheet coated with the surfactant tends to have good compatibility with hydrophilic components (plasma, etc.) in the blood, and tends to cause the blood body to remain in the top sheet. It is considered that the above-mentioned blood modifying agent has a low water solubility, and is different from the conventional surfactant, so that the top sheet is not left in the blood body and can be quickly moved to the absorber.

In the present specification, the solubility in 100 g of water at 25 ° C is referred to as "water solubility".

The above blood modifying agent may have a water solubility of about 0.00 g. Therefore, in the above blood modifying agent, the lower limit of the water solubility is about 0.00 g.

The above blood modifying agent has a weight average molecular weight of less than about 1,000, preferably a weight average molecular weight of less than about 900. Since the weight average molecular weight is about 1,000 or more, the blood modifying agent itself is sticky, which tends to make the user unpleasant. Further, when the weight average molecular weight is increased, the viscosity of the blood modifying agent tends to increase, and it becomes difficult to increase the viscosity of the blood modifying agent to a viscosity suitable for coating by heating. This result creates a situation where the blood modifying agent must be diluted with a solvent.

The above blood modifying agent is preferably a weight average molecular weight of about 100 or more, and more preferably a weight average molecular weight of about 200 or more. When the weight average molecular weight is small, there is a problem that the vapor pressure is high, vaporization during storage, reduction in the amount of the blood modifying agent, and odor during use.

In the present specification, the "weight average molecular weight" includes a compound derived from a polydisperse system (for example, a compound produced by sequential polymerization, a plurality of fatty acids, an ester formed with a plurality of aliphatic monovalent alcohols), and a single compound (for example). The concept of an ester produced by one type of fatty acid and one type of aliphatic monovalent alcohol is a molecule composed of N _i molecular weights M _i (i=1, or i=1, 2...). In the system, the following formula: M _w =ΣN _i M _i ² /ΣN _i M _i

The obtained M _w .

In the present specification, the weight average molecular weight means a value in terms of polystyrene obtained by colloidal permeation chromatography (GPC).

The measurement conditions of GPC are, for example, the following.

Model: High-speed liquid chromatogram by Hitachi High-Technologies Lachrom Elite

Pipe column: SHODEX KF-801, KF-803 and KF-804 made by Showa Denko Electric Co., Ltd.

Dissolution: THF

Flow rate: 1.0mL/min

Injection volume: 100μL

Detection: RI (differential refractometer)

Moreover, the weight average molecular weight described in the examples of the present specification is measured under the above conditions.

Preferably, the blood modifying agent is selected from the group consisting of (i) to (iii), (i) a hydrocarbon, (ii) a CC single bond having (ii-1) a hydrocarbon moiety and (ii-2) the hydrocarbon moiety. Inserting one or a plurality of compounds of the same or different groups selected from the group consisting of a carbonyl group (-CO-) and an oxy group (-O-), and (iii) having a hydrocarbon moiety (iii-1), and Iii-2) interposing between CC single bonds of the above hydrocarbon moiety, one or a plurality of identical or different groups selected from the group consisting of a carbonyl group (-CO-) and an oxy group (-O-), and (iii-3) a compound in which one or a plurality of the same or different groups selected from the group consisting of a carboxyl group (-COOH) and a hydroxyl group (-OH), which are substituted for a hydrogen atom of the above hydrocarbon moiety, and any combination thereof group.

In the present specification, the "hydrocarbon" is a compound composed of carbon and hydrogen, and the chain hydrocarbon may, for example, be a liquid paraffinic hydrocarbon (also referred to as an alkane having no double or triple bond) or an olefinic hydrocarbon (also including one). Double bond olefins), acetylene hydrocarbons (Also known as an alkyne having one triple bond), and a hydrocarbon selected by a group comprising two or more double bonds and triple bonds, and a cyclic hydrocarbon, for example, an aromatic hydrocarbon or an alicyclic hydrocarbon .

The hydrocarbon is preferably a chain hydrocarbon or an alicyclic hydrocarbon, more preferably a chain hydrocarbon, a liquid paraffin hydrocarbon, an olefin hydrocarbon, and a hydrocarbon having two or more double bonds (excluding a triple bond), and further preferably Liquid paraffinic hydrocarbons are the best.

The chain hydrocarbons include linear hydrocarbons and branched hydrocarbons.

In the compounds of the above (ii) and (iii), when two or more oxy groups (-O-) are inserted, each of the oxy groups (-O-) is not adjacent to each other. Therefore, among the compounds of the above (ii) and (iii), the compound in which the oxy group is continuous (that is, the peroxide) is not contained.

Further, in the compound of the above (iii), at least one hydrogen atom of the hydrocarbon moiety is substituted with a hydroxyl group (-OH) as compared with a compound in which at least one hydrogen atom of the hydrocarbon moiety is substituted by a carboxyl group (-COOH). Compounds are preferred. As shown in Table 1, since the carboxyl group is bonded to the metal in the menstrual blood, and the inorganic value is greatly increased from 150 to 400 or more, the blood modifying agent having a carboxyl group has a value of IOB of more than about 0.60 when used. The possibility of a decrease in blood cell affinity.

More preferably, the above blood modifying agent is selected from the group consisting of (i') to (iii'), (i') hydrocarbon, (ii') having (ii'-1) hydrocarbon portion and (ii'-2) hydrocarbon Part of the CC single bond is inserted in a group consisting of a carbonyl bond (-CO-), an ester bond (-COO-), a carbonate bond (-OCOO-), and an ether bond (-O-). One or more of the same or different bonded compounds, and (iii') a carbonyl bond (-CO-), an ester bond (-COO-), having a (iii'-1) hydrocarbon moiety, and (iii'-2) a CC bond of the above hydrocarbon moiety, One or a plurality of identical or different bonds selected from the group consisting of carbonate linkages (-OCOO-) and ether linkages (-O-), and (iii'-3) replacing hydrogen of the above hydrocarbon moiety A group of one or a plurality of compounds of the same or different groups selected from a group consisting of a carboxyl group (-COOH) and a hydroxyl group (-OH), and a combination of any of them.

In the above compounds (ii') and (iii'), when two or more identical or different bonds are inserted, that is, two or more carbonyl bond (-CO-) and ester bond are inserted ( Where -COO-), carbonate linkage (-OCOO-), and ether linkage (-O-) are selected for the same or different linkages, the linkages are not adjacent, at least between the linkages 1 carbon atom.

The blood modifying agent is further preferably selected from the group consisting of the following (A) to (F), (A) (A1) having a chain hydrocarbon moiety and two to four hydroxyl groups replacing the hydrogen atom of the chain hydrocarbon moiety; a compound, an ester having a chain hydrocarbon moiety with (A2), a compound having a carboxyl group substituted for a hydrogen atom of the above-mentioned chain hydrocarbon moiety, (B) (B1) having a chain hydrocarbon moiety, and a substitution of the above-mentioned chain hydrocarbon moiety a compound having 2 to 4 hydroxyl groups of a hydrogen atom, an ether having a chain hydrocarbon moiety (B2), a compound having a hydroxyl group substituted for a hydrogen atom of the chain hydrocarbon moiety, and (C) (C1) having a chain shape a hydrocarbon moiety, a carboxylic acid having 2 to 4 carboxyl groups substituted for a hydrogen atom of the above-mentioned chain hydrocarbon moiety, a hydroxy acid, an alkoxy acid or a pendant oxyacid, a chain hydrocarbon moiety with (C2), and a substituted chain An ester of a compound having one hydroxyl group of a hydrogen atom of a hydrocarbon moiety, (D) having a chain hydrocarbon moiety, and an ether bond (-O-), a carbonyl bond interposed between a CC single bond of the above-mentioned chain hydrocarbon moiety. (-CO-), ester linkage (-COO-), and carbonate linkage (-OCOO-) selected from any one of the compounds, (E) polyoxygenated C ₃ ~ C ₆ alkanediol Or the alkyl ester or alkyl ether, and (F a group of chain hydrocarbons and any combination thereof.

Hereinafter, the blood modifying agent will be described in detail based on (A) to (F).

[(A) (A1) has a chain hydrocarbon moiety, a compound having 2 to 4 hydroxyl groups which replaces a hydrogen atom of the above-mentioned chain hydrocarbon moiety, a chain hydrocarbon moiety with (A2), and a chain hydrocarbon moiety An ester of a compound having one carboxyl group of a hydrogen atom]

(A) (A1) a compound having a chain hydrocarbon moiety and 2 to 4 hydroxyl groups which replace the hydrogen atom of the above chain hydrocarbon moiety, (A2) having a chain hydrocarbon moiety, and a hydrogen replacing the above chain hydrocarbon moiety An ester of a compound having one carboxyl group of an atom (hereinafter also referred to as "the compound (A)") may have all of the hydroxyl groups not esterified under the above-mentioned IOB, melting point and water solubility.

(A1) a compound having a chain hydrocarbon moiety and 2 to 4 hydroxyl groups which replace a hydrogen atom of the above-mentioned chain hydrocarbon moiety (hereinafter, also referred to as "a compound In the case of (A1)", for example, a chain hydrocarbon tetraol, such as an alkanetetraol, for example, pentaerythritol, a chain hydrocarbon triol, such as an alkane triol, such as glycerin, and a chain hydrocarbon diol such as an alkane diol, may be mentioned. For example, a diol.

(A2) A compound having a chain hydrocarbon moiety and one carboxyl group which replaces the hydrogen atom of the chain hydrocarbon moiety (hereinafter also referred to as "compound (A2)"), for example, one hydrogen on a hydrocarbon A compound in which an atom is substituted with one carboxyl group (-COOH), for example, a fatty acid.

The compound (A) may, for example, be an ester of (a ₁ ) a chain hydrocarbon tetraol with at least one fatty acid, an ester of (a ₂ ) a chain hydrocarbon triol with at least one fatty acid, and (a ₃ ) a chain. An ester of a hydrocarbon diol with at least one fatty acid.

[(a ₁ ) an ester of a chain hydrocarbon tetraol with at least one fatty acid]

The ester of the above chain hydrocarbon tetraol and at least one fatty acid may, for example, be represented by the following formula (1): a tetraester of pentaerythritol and a fatty acid, and the following formula (2): a pentaerythritol and a fatty acid triester, the following formula (3): Diester of pentaerythritol and fatty acid, formula (4): a monoester of pentaerythritol and a fatty acid. (wherein, R ¹ to R ⁴ are each a chain hydrocarbon)

In the case of the fatty acid (R ¹ COOH, R ² COOH, R ³ COOH, and R ⁴ COOH) constituting the ester of pentaerythritol and a fatty acid, if the ester of pentaerythritol and a fatty acid is required to satisfy the above IOB, melting point, and water solubility, then Particularly limited, but for example, saturated fatty acids, such as C ₂ ~ C ₃₀ saturated fatty acids, such as acetic acid (C ₂ ) (C ₂ is a carbon number, equivalent to the carbon number of R ¹ C, R ² C, R ³ C or R ⁴ C , the same as below), propane acid (C ₃ ), butanoic acid (C ₄ ) and isomers thereof, such as 2-methylpropanic acid (C ₄ ), pentanoic acid (C ₅ ) and isomers thereof, For example, 2-methylbutanoic acid (C ₅ ), 2,2-dimethylpropane acid (C ₅ ), hexane acid (C ₆ ), heptanoic acid (C ₇ ), octanoic acid (C ₈ ) And isomers thereof, such as 2-ethylhexane acid (C ₈ ), decanoic acid (C ₉ ), decanoic acid (C ₁₀ ), dodecanoic acid (C ₁₂ ), myristic acid (C ₁₄ ), palmitic acid (C ₁₆ ), heptadecanoic acid (C ₁₇ ), octadecanoic acid (C ₁₈ ), eicosanoic acid (C ₂₀ ), behenic acid (C ₂₂ ), two Myristic acid (C ₂₄ ), dihexadecanoic acid (C ₂₆ ), octadecanoic acid (C ₂₈ ), triacontanic acid (C ₃₀ ), etc. and the isomers thereof (except for the above) .

The above fatty acid may in turn be an unsaturated fatty acid. The above unsaturated fatty acid may, for example, be a C ₃ - C ₂₀ unsaturated fatty acid such as a monounsaturated fatty acid such as crotonic acid (C ₄ ), tetradecenoic acid (C ₁₄ ) or hexadecenoic acid (C _16). ), oleic acid (C ₁₈ ), trans-octadecenoic acid (C ₁₈ ), octadecenoic acid (C ₁₈ ), eicosenoic acid (C ₂₀ ), eicosenoic acid (C ₂₀ ), etc. a di-unsaturated fatty acid, such as a triunsaturated fatty acid such as linoleic acid (C ₁₈ ) or eicosadienoic acid (C ₂₀ ), such as linoleic acid, such as α-linolenic acid (C ₁₈ ) and γ-linseed oil Acid (C ₁₈ ), pine nut oleic acid (C ₁₈ ), tung oil, such as α-tricoleic acid (C ₁₈ ) and β-ternic acid (C ₁₈ ), metic acid (C ₂₀ ), di- γ- sesame oil acid (C _20), eicosatrienoic acid (C ₂₀₎ and other four unsaturated fatty acids such as stearidonic acid (C _20), peanut tetracarboxylic acid (C _20), arachidonic acid ( C ₂₀ ), such as a penta-unsaturated fatty acid, such as bosseopentaenoic acid (C ₁₈ ), eicosapentaenoic acid (C ₂₀ ), and the like, and a partial hydrogen adduct thereof.

The above-mentioned esters of pentaerythritol and fatty acids, if considering the denaturation such as oxidation The possibility comes from an ester of a saturated fatty acid, pentaerythritol and a fatty acid, that is, an ester of pentaerythritol and a saturated fatty acid.

Further, in the ester of the pentaerythritol and the fatty acid, in order to make the IOB smaller and more hydrophobic, a diester, a triester or a tetraester is preferred, a triester or a tetraester is more preferable, and a tetraester is preferred.

The sum of the carbon number of the fatty acid of the pentaerythritol and the fatty acid, which is the tetraester of the pentaerythritol and the fatty acid, that is, the R ¹ C, R ² C, R ³ C and R ⁴ C parts in the above formula (1) When the total carbon number is 15, the IOB becomes 0.60. Therefore, in the case where the above-mentioned pentaerythritol and the fatty acid tetraester have a total carbon number of about 15 or more, the IOB satisfies the requirements of about 0.00 to about 0.60.

a tetraester of pentaerythritol and a fatty acid, such as pentaerythritol, hexane acid (C ₆ ), heptanoic acid (C ₇ ), octanoic acid (C ₈ ), for example, with 2-ethyl hexane acid (C ₈ ) , nonanoic acid (C _9), capric acid (C ₁₀₎ and / or lauric acid (C ₁₂₎ of the tetraester.

In the above-mentioned formula (2), the total number of carbon atoms of the R ¹ C, R ² C and R ³ C moieties is the sum of the carbon number of the fatty acid triester of the pentaerythritol and the fatty acid. At 19 o'clock, the IOB became 0.58. Therefore, in the case where the total number of carbon atoms of the above-mentioned pentaerythritol and fatty acid triester and fatty acid is about 19 or more, the IOB satisfies the requirements of about 0.00 to about 0.60.

In the case where the diester of the pentaerythritol and the fatty acid constitutes a total of the carbon number of the fatty acid of the pentaerythritol and the diester of the fatty acid, that is, when the carbon number of the R ¹ C and R ² C portions in the above formula (3) is 22 in total, The IOB became 0.59. Therefore, in the case where the total number of carbon atoms of the above-mentioned pentaerythritol and fatty acid diester and fatty acid is about 22 or more, the IOB meets the requirements of about 0.00 to about 0.60.

In the monoester of pentaerythritol and a fatty acid, the carbon number of the fatty acid constituting the monoester of pentaerythritol and a fatty acid, that is, in the above formula (4), when the carbon number of the R ¹ C moiety is 25, the IOB is 0.60. Therefore, in the case where the above-mentioned pentaerythritol and the monoester of the fatty acid have a carbon number of about 25 or more, the IOB satisfies the requirements of about 0.00 to about 0.60.

Further, in the above calculation, the effects of the double bond, the triple bond, the iso branch, and the tert branch are not considered.

The commercially available ester of the above-mentioned ester of pentaerythritol and a fatty acid may, for example, be UNISTAR H-408BRS or H-2408BRS-22 (mixed product) (above, manufactured by Nippon Oil Co., Ltd.).

[(a ₂ ) an ester of a chain hydrocarbon triol with at least one fatty acid]

The ester of the above-mentioned chain hydrocarbon triol and at least one fatty acid may, for example, be represented by the following formula (5): The triglyceride of glycerol and fatty acid, the following formula (6): The diester of glycerol and fatty acid, and the following formula (7): (wherein, R ⁵ to R ⁷ are each a chain hydrocarbon) a monoester of glycerin and a fatty acid.

In the case of the fatty acid (R ⁵ COOH, R ⁶ COOH, and R ⁷ COOH) constituting the ester of glycerin and a fatty acid, the ester of glycerin and a fatty acid is not particularly limited as long as it satisfies the requirements of the above IOB, melting point, and water solubility, for example, " (a ₁ ) fatty acids exemplified in the esters of chain hydrocarbon tetraols with at least one fatty acid, that is, saturated fatty acids and unsaturated fatty acids, and glycerol and fatty acids derived from saturated fatty acids, considering the possibility of denaturation such as oxidation The ester, that is, the ester of glycerin and a saturated fatty acid is preferred.

Further, in order to make the IOB smaller and more hydrophobic, the ester of the glycerin and the fatty acid is preferably a diester or a triester, and more preferably a triester.

The above triglyceride of glycerol and fatty acid is also called triglyceride, such as triester of glycerol and octanoic acid (C ₈ ), triester of glycerol and decanoic acid (C ₁₀ ), glycerol and dodecanoic acid (C ₁₂ ) a triester, and a triester of glycerin with two or three fatty acids, and mixtures thereof.

Examples of the glycerin and the triester of two or more kinds of fatty acids include triglycerides of glycerol and octanoic acid (C ₈ ) and decanoic acid (C ₁₀ ), glycerin and octanoic acid (C ₈ ), and decanoic acid ( C ₁₀ ) and the triester of dodecanoic acid (C ₁₂ ), glycerol and octanoic acid (C ₈ ), decanoic acid (C ₁₀ ), dodecanoic acid (C ₁₂ ), myristic acid (C ₁₄ ), a triester of palmitic acid (C ₁₆ ) and octadecanoic acid (C ₁₈ ).

In the above-mentioned glycerin and fatty acid triester, in order to make the melting point be lower than about 45 ° C, the total number of carbon atoms of the fatty acid constituting the triester of glycerin and fatty acid, that is, R ⁵ C, R ⁶ C and R in the formula (5) The carbon number of the ⁷ C portion is preferably about 40 or less in total.

Further, the total number of carbon atoms of the fatty acid triglyceride constituting the glycerin and the fatty acid triester, that is, the total number of carbon atoms in the R ⁵ C, R ⁶ C and R ⁷ C portions in the formula (5) For the 12th case, the IOB becomes 0.60. Therefore, in the case where the total number of carbon atoms of the glycerin and the fatty acid triester and the fatty acid is about 12 or more, the IOB satisfies the requirements of about 0.00 to about 0.60.

The above-mentioned triglyceride of glycerin and fatty acid is also a fat, because it can constitute a component of the human body, and is preferable from the viewpoint of safety.

The commercially available product of the above-mentioned glycerin and fatty acid triester may, for example, be tricocohol fatty acid glyceride, NA36, Panaseate 800, Panasete 800B, and Panaseate 810S, and tri-C2L oil fatty acid glyceride and tri-CL oil fatty acid glyceride (above, Nippon Oil Co., Ltd.) Company system) and so on.

The above diesters of glycerol and fatty acid, also known as diglycerides, such as diesters of glycerol and decanoic acid (C ₁₀ ), diesters of glycerol and dodecanoic acid (C ₁₂ ), glycerol and palmitic acid (C ₁₆ ) a diester, and a diester of glycerin and two fatty acids, and mixtures thereof.

In the total of the carbon number of the glycerin and the fatty acid diester which constitute the diester of the glycerin and the fatty acid, that is, in the formula (6), when the total carbon number of the R ⁵ C and R ⁶ C portions is 16, the IOB becomes 0.58. Therefore, in the case where the total number of carbon atoms of the glycerin and the fatty acid diester and the fatty acid is about 16 or more, the IOB meets the requirements of about 0.00 to about 0.60.

The monoester of the above glycerin and fatty acid is also called a monoglyceride, for example, an eicosanoic acid (C ₂₀ ) monoester of glycerin, a behenic acid (C ₂₂ ) monoester of glycerin or the like.

In the monoester of glycerin and a fatty acid, the carbon number of the fatty acid constituting the monoester of glycerin and a fatty acid, that is, in the formula (7), when the carbon number of the R ⁵ C moiety is 19, the IOB is 0.59. Therefore, in the case where the carbon number of the glycerin and the fatty acid monoester and the fatty acid is about 19 or more, the IOB satisfies the requirements of about 0.00 to about 0.60.

[(a ₃ ) ester of a chain hydrocarbon diol with at least one fatty acid]

The ester of the chain hydrocarbon diol and at least one fatty acid may, for example, be a C ₂ -C ₆ chain hydrocarbon diol, for example, a C ₂ -C ₆ diol such as ethylene glycol, propylene glycol or butylene glycol. a monoester or diester of pentanediol or hexanediol with a fatty acid.

Specifically, the ester of the chain hydrocarbon diol and at least one fatty acid may, for example, be represented by the following formula (8): R ⁸ COOC _k H _2k OCOR ⁹ (8) (wherein k is an integer of 2 to 6, Then R ⁸ and R ⁹ are each a chain hydrocarbon (C ₂ -C ₆ diol) and a fatty acid diester, and the following formula (9): R ⁸ COOC _k H _2k OH (9) (where k is An integer of from 2 to 6, followed by R ⁸ being a chain hydrocarbon) of a C ₂ -C ₆ diol and a monoester of a fatty acid.

Among the above esters of C ₂ -C ₆ diol and fatty acid, the fatty acid to be esterified (in the formulas (8) and (9), which is equivalent to R ⁸ COOH and R ⁹ COOH), the C ₂ -C ₆ diol and The ester of a fatty acid is not particularly limited as long as it satisfies the requirements of the above IOB, melting point, and water solubility. For example, the fatty acid listed in the "(a ₁ ) chain hydrocarbon tetraol and at least one fatty acid ester", that is, saturated. For fatty acids and unsaturated fatty acids, it is preferred to use saturated fatty acids in consideration of the possibility of denaturation such as oxidation.

When the total number of carbon atoms of the butanediol (k=4) represented by the formula (8) and the diester of the fatty acid and the R ⁸ C and R ⁹ C moieties is 6, the IOB becomes 0.60. Therefore, in the case where the butanediol (k=4) represented by the formula (8) and the diester of the fatty acid have a total carbon number of about 6 or more, the IOB satisfies the requirements of about 0.00 to about 0.60. Further, in the case of the ethylene glycol (k = 2) represented by the formula (9) and the monoester of the fatty acid, and the carbon number of the R ⁸ C moiety is 12, the IOB is 0.57. Therefore, in the case where the ethylene glycol (k = 2) represented by the formula (9) and the monoester of the fatty acid and the carbon number of the fatty acid are about 12 or more, the IOB satisfies the requirements of about 0.00 to about 0.60.

In the case of the above-mentioned ester of a C ₂ -C ₆ diol and a fatty acid, considering the possibility of denaturation such as oxidation, an ester of a C ₂ -C ₆ diol derived from a saturated fatty acid and a fatty acid, that is, a C ₂ -C ₆ diol is used. Esters of saturated fatty acids are preferred.

Further, in the ester of a C ₂ -C ₆ diol and a fatty acid, in order to make IOB smaller and more hydrophobic, an ester of a diol derived from a diol having a large carbon number and a fatty acid, for example, from butanediol, The ester of a diol of pentanediol or hexanediol with a fatty acid is preferred.

Further, in terms of the ester of the C ₂ -C ₆ diol and the fatty acid, in order to make the IOB smaller and more hydrophobic, it is preferred to use a diester.

The commercially available product of the above-mentioned ester of a C ₂ -C ₆ diol and a fatty acid may, for example, be a Cobopol BL or a Cotomboru BS (manufactured by Nippon Oil Co., Ltd.).

[(B) (B1) a compound having a chain hydrocarbon portion, a 2-4 hydroxyl group substituted for a hydrogen atom of the above-mentioned chain hydrocarbon portion, a chain hydrocarbon portion with (B2), and a chain hydrocarbon portion substituted for Ether of a hydroxyl group of a hydrogen atom]

(B) (B1) a compound having a chain hydrocarbon moiety and 2 to 4 hydroxyl groups which replace a hydrogen atom of the above-mentioned chain hydrocarbon moiety, (B2) having a chain hydrocarbon moiety, and hydrogen replacing the above chain hydrocarbon moiety The ether of the compound having one hydroxyl group of the atom (hereinafter also referred to as "the compound (B)") may have not all of the hydroxyl groups etherified by the above-mentioned IOB, melting point and water solubility.

(B1) A compound having a chain hydrocarbon moiety and 2 to 4 hydroxyl groups which replace the hydrogen atom of the chain hydrocarbon moiety (hereinafter also referred to as "compound (B1)"), for example, (A)" As the compound (A1), for example, pentaerythritol, glycerin, and a diol are exemplified.

(B2) A compound having a chain hydrocarbon moiety and one hydroxyl group which replaces the hydrogen atom of the chain hydrocarbon moiety (hereinafter, also referred to as "compound (B2)"), for example, one hydrogen atom of a hydrocarbon A compound substituted with one hydroxyl group (-OH), for example, an aliphatic monovalent alcohol, for example, a saturated aliphatic monovalent alcohol and an unsaturated aliphatic monovalent alcohol.

The saturated aliphatic monovalent alcohol may, for example, be a C ₁ to C ₂₀ saturated aliphatic monovalent alcohol, for example, a methyl alcohol (C ₁ ) (C ₁ is a carbon number, the same applies hereinafter), and an ethyl alcohol (C ₂ ). , propyl alcohol (C ₃ ) and isomers thereof, such as isopropyl alcohol (C ₃ ), butyl alcohol (C ₄ ) and isomers thereof, such as sec-butyl alcohol (C ₄ ) and tert- Butyl alcohol (C ₄ ), pentyl alcohol (C ₅ ), hexyl alcohol (C ₆ ), heptyl alcohol (C ₇ ), octyl alcohol (C ₈ ) and isomers thereof, such as 2-ethylhexyl alcohols (C _8), nonyl alcohol (C _9), decyl alcohol (C _10), dodecyl alcohol (C _12), tetradecyl alcohol (C _14), cetyl alcohol (C _16), Heptadecyl alcohol (C ₁₇ ), octadecyl alcohol (C ₁₈ ), and eicosyl alcohol (C ₂₀ ), and the unexemplified isomers.

The unsaturated aliphatic monovalent alcohol may, for example, be one in which one of the CC single bonds of the above saturated aliphatic monovalent alcohol is substituted with a C=C double bond, for example, an oleyl alcohol, for example, a new Japanese physicochemical company with a Rikacol series. And the Anjie Kelu series name is sold.

The compound (B) may, for example, be an ether of a (b ₁ ) chain hydrocarbon tetraol and at least one aliphatic monovalent alcohol, for example, a monoether, a diether, a triether and a tetraether, preferably a diether or a trisole. Ethers and tetraethers, more preferably triethers and tetraethers, still more preferably tetraethers, (b ₂ ) chain hydrocarbon triols and at least one ether of an aliphatic monovalent alcohol, such as monoethers, diethers and a triether, preferably a diether and a triether, more preferably a triether, and (b ₃ ) a chain hydrocarbon diol and an ether of at least one aliphatic monovalent alcohol, such as a monoether and a diether, followed by Preferred is a diether.

Examples of the ether of the chain hydrocarbon tetraol and at least one aliphatic monovalent alcohol include the following formulas (10) to (13): (wherein, R ¹⁰ to R ¹³ are each a chain hydrocarbon) a pentaerythritol and a tetraether of an aliphatic monovalent alcohol, a triether, a diether, and a monoether.

Examples of the ether of the chain hydrocarbon triol and at least one aliphatic monovalent alcohol include the following formulas (14) to (16): (wherein R ¹⁴ to R ¹⁶ are each a chain hydrocarbon.)

A triglyceride, a diether, and a monoether of glycerin and at least one aliphatic monovalent alcohol.

The ether of the chain hydrocarbon diol and the aliphatic monovalent alcohol may, for example, be represented by the following formula (17): R ¹⁷ OC _n H _2n OR ¹⁸ (17) (wherein n is an integer of 2 to 6, and then R ¹⁷ and R ¹⁸ each represent a chain hydrocarbon) of C ₂ ~ C ₆ monovalent aliphatic diol and bis ether alcohols, and the following formula _{^{(18): R 17 OC n}} H 2n OH (18) ( wherein, n It is an integer of 2-6, followed by R ¹⁷ being a chain hydrocarbon) of a C ₂ -C ₆ diol and a monoether of an aliphatic monovalent alcohol.

The total number of carbon atoms of the aliphatic monovalent alcohol constituting the tetraether of the pentaerythritol and the aliphatic monovalent alcohol in the tetraether of the pentaerythritol and the aliphatic monovalent alcohol, that is, R ¹⁰ and R ¹¹ in the above formula (10) When the total number of carbon atoms in the R ¹² and R ¹³ portions is 4, the IOB becomes 0.44. Therefore, in the case where the total number of carbon atoms of the above-mentioned pentaerythritol and the aliphatic monovalent alcohol and the aliphatic monovalent alcohol is about 4 or more, the IOB satisfies the requirements of about 0.00 to about 0.60.

The sum of the carbon number of the above-mentioned pentaerythritol and the trivalent ether of an aliphatic monovalent alcohol, which constitutes an aliphatic monovalent alcohol of pentaerythritol and a triether of an aliphatic monovalent alcohol, that is, R ¹⁰ and R ¹¹ in the above formula (11) When the total carbon number of the R ¹² portion is 9, the IOB becomes 0.57. Therefore, when the total number of carbon atoms of the above-mentioned pentaerythritol and the aliphatic trivalent alcohol and the aliphatic monovalent alcohol is about 9 or more, the IOB satisfies the requirements of about 0.00 to about 0.60.

The sum of the carbon numbers of the above-mentioned pentaerythritol and the diester of the aliphatic monovalent alcohol, which constitutes the aliphatic monovalent alcohol of the pentaerythritol and the diester of the aliphatic monovalent alcohol, that is, R ¹⁰ and R ¹¹ in the above formula (12) When the total carbon number is 15, the IOB becomes 0.60. Therefore, in the case where the carbon number of the aliphatic monovalent alcohol in the diether of the pentaerythritol and the aliphatic monovalent alcohol is about 15 or more in total, the IOB satisfies the requirement of about 0.00 to about 0.60.

In the monoether of the pentaerythritol and the aliphatic monovalent alcohol, the carbon number of the aliphatic monovalent alcohol constituting the monoether of the pentaerythritol and the aliphatic monovalent alcohol, that is, the carbon number of the R ¹⁰ portion in the above formula (13) is On the occasion of 22, the IOB became 0.59. Therefore, in the case where the monoether of the pentaerythritol and the aliphatic monovalent alcohol constitutes an aliphatic monovalent alcohol having a carbon number of about 22 or more, the IOB satisfies the requirements of from about 0.00 to about 0.60.

Further, in the triether of the glycerin and the aliphatic monovalent alcohol, the total number of carbon atoms of the aliphatic monovalent alcohol constituting the triether of glycerin and the aliphatic monovalent alcohol, that is, R ¹⁴ and R in the formula (14) ^{When the} total number of carbon atoms in the ¹⁵ and R ¹⁶ portions is 3, the IOB becomes 0.50. Therefore, when the total number of carbon atoms of the glycerin and the aliphatic monovalent alcohol triol constituting the aliphatic monovalent alcohol is about 3 or more, the IOB satisfies the requirements of about 0.00 to about 0.60.

The total number of carbon atoms of the aliphatic monovalent alcohol constituting the diester of glycerin and the aliphatic monovalent alcohol in the diether of the glycerin and the aliphatic monovalent alcohol, that is, the R ¹⁴ and R ¹⁵ portions in the formula (15) When the total carbon number is 9, the IOB becomes 0.58. Therefore, when the total amount of carbon atoms of the glycerin and the aliphatic monovalent alcohol and the aliphatic monovalent alcohol is about 9 or more, the IOB satisfies the requirements of about 0.00 to about 0.60.

In the monoether of the glycerin and the aliphatic monovalent alcohol, the carbon number of the aliphatic monovalent alcohol constituting the monoether of glycerin and the aliphatic monovalent alcohol, that is, the carbon number of the R ¹⁴ moiety in the formula (16) is 16 At the time, the IOB became 0.58. Therefore, in the case where the monoether of the glycerin and the aliphatic monovalent alcohol constitutes an aliphatic monovalent alcohol having a carbon number of about 16 or more, the IOB satisfies a requirement of from about 0.00 to about 0.60.

In the case where the number of carbon atoms of the R ¹⁷ and R ¹⁸ moieties of the dibutyl diol (n = 4) represented by the formula (17) and the aliphatic monovalent alcohol is 2, the IOB is 0.33. Therefore, when the total number of carbon atoms of the divalent diol (n=4) represented by the formula (17) and the aliphatic monovalent alcohol and the aliphatic monovalent alcohol is 2 or more, the IOB is in the range of about 0.00 to about 0.60. The essentials. Further, in the case of the ethylene glycol (n = 2) represented by the formula (18) and the monoether of the aliphatic monovalent alcohol, and the carbon number of the R ¹⁷ moiety is 8, the IOB is 0.60. Therefore, in the case where the ethylene glycol (n=2) represented by the formula (18) and the monoether of the aliphatic monovalent alcohol and the aliphatic monovalent alcohol have a carbon number of about 8 or more, the IOB conforms to about 0.00 to about 0.60. The essentials.

In the case of the compound (B), the compound (B1) and the compound (B2) can be produced by dehydration condensation in the presence of an acid catalyst.

[(C)(C1) a carboxylic acid, a hydroxy acid, an alkoxy acid or a pendant oxy acid containing a chain hydrocarbon moiety and a 2-4 carboxyl group substituted for the hydrogen atom of the above-mentioned chain hydrocarbon moiety, and (C2) An ester having a chain hydrocarbon moiety and a compound substituted with one hydroxyl group of a hydrogen atom of the above-mentioned chain hydrocarbon moiety]

(C) (C1) a carboxylic acid having a chain hydrocarbon moiety and a 2-4 carboxyl group substituted for a hydrogen atom of the above-mentioned chain hydrocarbon moiety, a hydroxy acid, an alkoxy acid or a pendant acid, and (C2) An ester of a chain hydrocarbon moiety and a compound which replaces one hydroxyl group of a hydrogen atom of the above-mentioned chain hydrocarbon moiety (hereinafter also referred to as "compound (C)") has the above IOB, melting point and water solubility. The carboxyl groups may not all be esterified.

(C1) a carboxylic acid, a hydroxy acid, an alkoxy acid or a pendant oxyacid having a chain hydrocarbon moiety and 2 to 4 carboxyl groups which replace the hydrogen atom of the chain hydrocarbon moiety (hereinafter, also referred to as "compound ( In the case of C1)", for example, a chain hydrocarbon carboxylic acid having 2 to 4 carboxyl groups, for example, a chain hydrocarbon dicarboxylic acid, for example, an alkane dicarboxylic acid such as ethane diacid, propane diacid, butane 2 Acid, pentanedioic acid, hexanedioic acid, heptanedioic acid, octanedioic acid, decanedioic acid and decanedioic acid, chain hydrocarbon tricarboxylic acid, such as an alkanetricarboxylic acid, such as propane tricarboxylic acid, Butane triacid, pentane tricarboxylic acid, hexane tricarboxylic acid, heptane triacid, octane triacid, decane tricarboxylic acid and decane tricarboxylic acid, and chain hydrocarbon tetracarboxylic acid, such as alkanes Tetracarboxylic acids, such as butane tetracarboxylic acid, pentanetetracarboxylic acid, hexanetetracarboxylic acid, heptanetetracarboxylic acid, octane tetracarboxylic acid, decanetetracarboxylic acid, and decanetetracarboxylic acid.

Further, the compound (C1) includes a chain hydrocarbon hydroxy acid having 2 to 4 carboxyl groups, for example, malic acid, tartaric acid, citric acid, isocitric acid, or the like, and a chain hydrocarbon alkoxy acid having 2 to 4 carboxyl groups. For example, O-acetyl citrate and a chain hydrocarbon side oxyacid having 2 to 4 carboxyl groups.

(C2) The compound having a chain hydrocarbon moiety and one hydroxyl group which replaces the hydrogen atom of the above-mentioned chain hydrocarbon moiety may, for example, be exemplified by "compound (B)", for example, an aliphatic monovalent alcohol.

As the compound (c), (c ₁ ) an ester of a chain hydrocarbon tetracarboxylic acid having four carboxyl groups, a hydroxy acid, an alkoxy acid or a pendant acid and at least one aliphatic monovalent alcohol, for example, a monoester , diester, triesters and tetraesters, preferably diesters, triesters and tetraesters, more preferably triesters and triesters, more preferably tetraesters, (c ₂ ) chain hydrocarbons having 3 carboxyl groups An ester of a tricarboxylic acid, a hydroxy acid, an alkoxy acid or a pendant acid with at least one aliphatic monovalent alcohol, such as a monoester, a diester or a triester, preferably a diester and a triester, and more best triester, and (c ₃₎ having two carboxyl chain hydrocarbon dicarboxylic acid, hydroxy acid, alkoxy acid or oxo acid and at least one aliphatic ester of a monovalent alcohol, e.g. monoesters And a diester, preferably a diester.

Examples of the compound (C) include commercially available dioctyl adipate, diisostearyl malate, tributyl citrate, and O-acetyl butyl tributyl citrate. By.

[(D) an ether bond (-O-), a carbonyl bond (-CO-), an ester bond inserted between a chain hydrocarbon moiety and a C-C single bond of the above chain hydrocarbon moiety a compound selected from the group consisting of a knot (-COO-) and a carbonate bond (-OCOO-)]

(D) an ether bond (-O-), a carbonyl bond (-CO-), an ester bond (-COO-), and a chain hydrocarbon moiety interposed between the CC single bond of the chain hydrocarbon moiety, And any one of the compounds selected in the group of the carbonate bond (-OCOO-) (hereinafter also referred to as "the compound (D)"), for example, (d ₁ ) an aliphatic monovalent alcohol And an ester of an aliphatic monovalent alcohol, (d ₂ ) dialkyl ketone, (d ₃ ) fatty acid and an aliphatic monovalent alcohol, or (d ₄ ) dialkyl carbonate.

[(d ₁ ) an ether of an aliphatic monovalent alcohol and an aliphatic monovalent alcohol]

The ether of the aliphatic monovalent alcohol and the aliphatic monovalent alcohol may, for example, be a compound having the following formula (19): R ¹⁹ OR ²⁰ (19) (wherein each of R ¹⁹ and R ²⁰ is a chain hydrocarbon) .

In the case of the aliphatic monovalent alcohol (equivalent to R ¹⁹ OH and R ²⁰ OH in the formula (19)), the ether is not particularly limited as long as it satisfies the requirements of the above IOB, melting point and water solubility, for example, " An aliphatic monovalent alcohol exemplified in the item (B)".

In the total of the carbon number of the aliphatic monovalent alcohol and the aliphatic monovalent alcohol constituting the ether, that is, in the above formula (19), the total carbon number of the R ¹⁹ and R ²⁰ moieties is In the case of 2, since the IOB is 0.50, the total number of carbon atoms is about 2 or more, and the requirements of the above IOB are satisfied. However, the total carbon number is about 6 and the water solubility is about 2 g, which is also problematic from the viewpoint of vapor pressure. In order to satisfy the water solubility to a requirement of from about 0.00 to about 0.05 g, the above carbon number is preferably about 8 or more in total.

[(d ₂ )dialkyl ketone]

The dialkyl ketone may, for example, be a compound having the following formula (20): R ²¹ COR ²² (20) (wherein each of R ²¹ and R ²² is an alkyl group).

In the above dialkyl ketone, when the total number of carbon atoms of R ²¹ and R ²² is 5, the IOB is 0.54. Therefore, when the total carbon number is about 5 or more, the above IOB requirement is satisfied. However, the above carbon number is about 5 in total, and the water solubility is about 2 g. Therefore, in order to satisfy the water solubility of about 0.00 to about 0.05 g, the total carbon number is preferably about 8 or more. Further, when the vapor pressure is considered, the carbon number is preferably about 10 or more, and then about 12 or more.

Further, when the total carbon number is about 8, for example, 5-nonanone, the melting point is about -50 ° C, and the vapor pressure is about 230 Pa at 20 ° C.

The above dialkyl ketone can be obtained by a conventional method, for example, by oxidizing a second-stage alcohol with chromic acid or the like, in addition to a commercially available one.

[(d ₃ ) ester of fatty acid with aliphatic monovalent alcohol]

The ester of the above-mentioned fatty acid and the aliphatic monovalent alcohol may, for example, be a compound having the following formula (21): R ²³ COOR ²⁴ (21) (wherein each of R ²³ and R ²⁴ is a chain hydrocarbon).

The fatty acid constituting the above-mentioned ester (corresponding to R ²³ COOH in the formula (21)) may, for example, be a fatty acid listed in the "(a ₁ ) chain hydrocarbon tetraol and an ester of at least one fatty acid", that is, a saturated fatty acid or As the unsaturated fatty acid, it is preferable to use a saturated fatty acid in consideration of the possibility of denaturation such as oxidation. The aliphatic monovalent alcohol (equivalent to R ²⁴ OH in the formula (21)) constituting the above-mentioned ester may, for example, be an aliphatic monovalent alcohol exemplified in the item "Compound (B)".

Further, in the total of the carbon number of the fatty acid and the aliphatic monovalent alcohol, and the carbon number of the fatty acid and the aliphatic monovalent alcohol, that is, in the formula (21), when the carbon number of the R ²³ C and R ²⁴ portions is 5 in total, Since the IOB is 0.60, the total number of carbon atoms in the R ²³ C and R ²⁴ portions is about 5 or more, which satisfies the requirements of the above IOB. However, for example, in the case of the above-mentioned butyl acetate having a total carbon number of 6, the vapor pressure is as high as more than 2,000 Pa. Therefore, when the vapor pressure is considered, the total carbon number is preferably about 12 or more. Further, the total carbon number is about 11 or more, and the water solubility is preferably from about 0.00 to about 0.05 g.

Examples of the ester of the above fatty acid with an aliphatic monovalent alcohol include, for example, an ester of dodecanoic acid (C ₁₂ ) with lauryl alcohol (C ₁₂ ), myristic acid (C ₁₄ ) and dodecyl group. A commercially available product of an ester of an alcohol (C ₁₂ ), such as an ester of the above-mentioned fatty acid and an aliphatic monovalent alcohol, may be, for example, Eretru WE20 or Eretru WE40 (above, manufactured by Nippon Oil Co., Ltd.).

[(d ₄ )Dialkyl carbonate]

The dialkyl carbonate may, for example, be a compound having the following formula (22): R ²⁵ OC(=O)OR ²⁶ (22) (wherein each of R ²⁵ and R ²⁶ is an alkyl group).

In the above dialkyl carbonate, when the total carbon number of R ²⁵ and R ²⁶ is 6, the IOB is 0.57. Therefore, if the total carbon number of R ²⁵ and R ²⁶ is about 6 or more, the requirement of IOB is satisfied.

When the water solubility is considered, the total carbon number of R ²⁵ and R ²⁶ is preferably about 7 or more, more preferably about 9 or more.

The above dialkyl carbonates can be synthesized by the reaction of phosgene with an alcohol, the reaction of a chlorinated formate with an alcohol or an alkoxide, and the reaction of silver carbonate with an alkyl iodide, in addition to those commercially available.

[(E) polyoxygenated C ₃ ~C ₆ alkanediol, or the alkyl ester or alkyl ether]

(E) Polyoxygenated C ₃ -C ₆ alkanediol, or the alkyl ester or alkyl ether (hereinafter referred to as the case of the compound (E)), for example, (e ₁ ) polyoxygenated C ₃ -C ₆ alkanediol, (e ₂ ) polyoxygenated C ₃ -C ₆ alkanediol ester with at least one fatty acid, (e ₃ ) polyoxygenated C ₃ -C ₆ alkanediol and at least one aliphatic 1 An ether of a valence alcohol. The following is explained.

[(e ₁ ) Polyoxygenated C ₃ ~C ₆ alkanediol]

The above polyoxygenated C ₃ -C ₆ alkanediol refers to i) having an oxy C ₃ -C ₆ alkylene unit, that is, an oxypropylene unit, an oxybutylene unit, a pentene oxide unit, and an oxyhexene unit. a unit of any one selected from the group, having a homopolymer of a hydroxyl group at both ends, ii) a block copolymer having two or more units selected from the above group, and having a hydroxyl group at both ends, or iii) A random copolymer having two or more units selected from the above group and having a hydroxyl group at both ends.

The polyoxygenated C ₃ -C ₆ alkanediol is represented by the following formula (23): HO-(C _m H _2m O) _n -H (23) (wherein m is an integer of 3 to 6).

Further, in polyethylene glycol (formula (23), a homopolymer of m=2), when n≧45, although it meets the requirements of IOB of about 0.00 to about 0.60, the weight average molecular weight at n≧45 More than about 2,000.

Moreover, the inventors have confirmed that polypropylene glycol (a homopolymer equivalent to m = 3 in the formula (23)) satisfies an IOB of about 0.00 to about 0.60 and a temperature of about 45 ° C or less only when the weight average molecular weight is about 1,000 or more. The melting point of water is about 0.00 to about 0.05 g of water solubility for 100 g of water at 25 °C. Therefore, the homopolymer of polypropylene glycol is not included in the range of the above blood modifying agent.

Thus, a copolymer or random polymer of propylene glycol with other diols is included in the (e ₁ ) polyoxy C ₃ -C ₆ alkanediol.

In the above formula (23), the value of n is a polyoxygenated C ₃ -C ₆ alkanediol having an IOB of from about 0.00 to about 0.60, a melting point of about 45 ° C or less, and a water content of from about 0.00 to about 0.05 g per 100 g of water at 25 ° C. The value of water solubility.

For example, when the formula (23) is polytetramethylene glycol (m = 4), when n = 7, the IOB is 0.57. Therefore, when the formula (23) is a polytetramethylene glycol (m=4 homopolymer), when n≧ is about 7, the above-mentioned IOB requirements are satisfied.

For example, Uniol (trademark) PB-500 and PB-700 (all manufactured by Nippon Oil Co., Ltd.) can be used as a commercial product of the above-mentioned polyoxygenated C ₃ -C ₆ alkanediol.

[(e ₂ ) an ester of a polyoxygenated C ₃ -C ₆ alkanediol with at least one fatty acid]

The above-described polyoxyalkylene C ₃ ~ C ₆ alkanediol with at least one aspect of an ester of fatty acids, such as "(e ₁₎ polyoxy C ₃ ~ C ₆ alkanediol" Description of the polyoxyalkylene C ₃ ~ C ₆ alkyl One or both of the OH ends of the diol are esterified with fatty acids, i.e., monoesters and diesters.

Among the esters of the polyoxygenated C ₃ -C ₆ alkanediol and at least one of the fatty acids, the fatty acid to be esterified may, for example, be listed as "an ester of (a ₁ ) chain hydrocarbon tetraol and at least one fatty acid". The fatty acid, that is, a saturated fatty acid or an unsaturated fatty acid, is preferably a saturated fatty acid if the possibility of denaturation such as oxidation is considered.

[(e ₃ ) an ether of a polyoxygenated C ₃ -C ₆ alkanediol and at least one aliphatic monovalent alcohol]

The polyoxy C of the above-mentioned polyoxy C ₃ -C ₆ alkanediol and at least one aliphatic monovalent alcohol may, for example, be described as "(e ₁ ) polyoxygenated C ₃ -C ₆ alkanediol" One or both of the OH ends of ₃ to C ₆ alkanediol are etherified with an aliphatic monovalent alcohol, that is, a monoether and a diether.

In the ether of the polyoxy C ₃ -C ₆ alkanediol and at least one of the aliphatic monovalent alcohols, the aliphatic monovalent alcohol to be etherified may, for example, be the aliphatic 1 listed in the "compound (B)". Valence alcohol.

[(F) chain hydrocarbon]

The chain hydrocarbon may be contained in the blood modifying agent because the inorganic value is 0, the IOB is 0.00, and the water solubility is almost 0.00 g. Therefore, the melting point is about 45 ° C or lower. The chain hydrocarbon may, for example, be a (f ₁ ) chain alkane, for example, a linear alkane or a branched alkane. For example, in the case of a linear alkane, when the melting point is about 45 ° C or less, the carbon number is preferably 22 or less. Further, when the vapor pressure is considered, the carbon number is preferably 13 or more. When alkane is branched, the melting point is low in the same carbon number as compared with the linear alkane, and therefore, the carbon number may be 22 or more.

A commercially available product of the above hydrocarbons may, for example, be Parleam 6 (Nippon Oil Co., Ltd.).

The blood modifying agent was examined in detail in the examples and found to have at least a function of lowering the viscosity and surface tension of blood. The menstrual blood to be absorbed by the absorbent article is compared with the general blood, and the blood cells are connected to each other by the proteins such as the endometrial wall, and the blood cells are easily in a state of continuous alignment. Therefore, the menstrual blood to be absorbed by the absorbent article tends to become highly viscous, and when the top sheet is non-woven or woven, the menstrual blood is easily clogged between the fibers, the user feels sticky, and then spreads on the surface of the top sheet. It becomes easy to leak. Further, when the second sheet is a non-woven fabric or a woven fabric, the menstrual blood is likely to be clogged between the fibers, and the user feels sticky feeling.

In the absorbent article of the present invention, the top sheet contains a blood modifying agent having a function of lowering the viscosity and surface tension of the blood, and when the top sheet is a non-woven fabric or a woven fabric, the fibers of the top sheet are not easily blocked by the menstrual blood, and the menstrual blood can be The top sheet is quickly moved through the second sheet to the absorbent body.

Further, in the absorbent article of the present invention, it is considered that when the melting point of the blood modifying agent is about 45 ° C or lower, whether it is a liquid or a solid at normal temperature (25 ° C), and when it comes into contact with a body fluid of about 30 to about 40 ° C, Liquefaction (or liquid), easy to dissolve in body fluids.

Further, it is considered that the blood modifying agent having an IOB of about 0.00 to about 0.60 has high organicity and easily enters between blood cells, and the blood cells can be stabilized, and the blood cells are less likely to form a continuous array structure.

It is considered that the above-mentioned modifier is such that the blood cells are stabilized and the blood cells are not easily formed into a continuous array structure, and the absorber easily absorbs menstrual blood. For example, it is known that an acrylic high-absorbent polymer, that is, an absorbent article containing SAP, absorbs menstrual blood, and the continuously arranged blood cells coat the surface of the SAP, and it becomes difficult for SAP to exert absorption performance, but by setting the blood cell to be stable, SAP It becomes easy to exert absorption performance. Further, it is considered that the red blood cell membrane is not easily destroyed by the blood modifying agent having a high affinity with red blood cells to protect the red blood cell membrane.

In the absorbent article according to the first aspect of the present invention, the top sheet and the second sheet contain a blood modifying agent, and the absorbent article according to another embodiment of the present invention, the top sheet and/or the second sheet contains only the blood modifying agent. Next, in the absorbent article according to another embodiment of the present invention, the top sheet and/or the second sheet contains a blood modifying agent-containing composition containing a blood modifying agent and at least one other component.

Hereinafter, the composition containing the blood modifying agent will be described.

[The blood modifying agent contains a composition]

The blood modifying agent contains a composition containing at least one kind of blood modifying agent Other ingredients.

The other components of the above-mentioned at least one kind are not particularly limited as long as they do not inhibit the effects of the present invention, and are generally used in the industry, for example, in absorbent articles, particularly top sheets.

The other components of at least one of the above may be, for example, an anthrone oil, an anthrone or an anthrone-based resin.

The other components of at least one of the above may, for example, be an antioxidant such as BHT (2,6-di-t-butyl-p-cresol), BHA (butylated hydroxyanisole), or propyl gallate. Wait.

The other components of at least one of the above may be, for example, a vitamin, for example, a natural vitamin or a synthetic vitamin. The above vitamins may, for example, be water-soluble vitamins such as vitamin B group, such as vitamin B ₁ , vitamin B ₂ , vitamin B ₃ , vitamin B ₅ , vitamin B ₆ , vitamin B ₇ , vitamin B ₉ , vitamin B _{12 ,} etc., vitamin C .

The vitamin may, for example, be a fat-soluble vitamin, for example, a vitamin A group, a vitamin D group, a vitamin E group, or a vitamin K group.

Further, the above vitamins also include their derivatives.

Examples of the other components of the above-mentioned at least one kind include an amino acid, for example, alanine, arginine, lysine, histidine, proline, hydroxyproline, and the like.

The other components of at least one of the above may, for example, be zeolites, for example, natural zeolites such as analcime, chabazite, stilbite, sodium zeolite, zeolite, and samarium manganese ore, and synthetic zeolites.

The other components of at least one of the above may be, for example, cholesterol or hyaluronic Acid, lecithin, ceramide, etc.

Further, examples of the at least one other component include a drug, for example, a skin astringent, an anti-acne agent, an anti-wrinkle agent, an anti-cellulite agent, a whitening agent, an antibacterial agent, an antifungal agent, and the like.

The skin astringent agent may, for example, be zinc oxide, aluminum sulfate or tannic acid, or an oil-soluble skin astringent agent such as an oil-soluble polyphenol. In the case of the above oil-soluble polyphenols, natural oil-soluble polyphenols, such as extracts of astragalus, small forsythia extract, stalk extract of stalk, chamomile extract, burdock extract, sage extract, extract of sorghum, Western Linden Tree Extract, White Birch Extract, E. striata Extract, Salvia Extract, Sage Extract, Hand Walnut Extract, Hibiscus Extract, Loquat Leaf Extract, Linden Extract, Hop Extract, Maroni extract, coix seed extract, etc.

Examples of the anti-acne agent include salicylic acid, benzammonium peroxide, resorcinol, sulfur, erythromycin, zinc, and the like.

Examples of the anti-wrinkle agent include lactic acid, salicylic acid, salicylic acid derivatives, glycolic acid, phytic acid, lipoic acid, and lysophosphatidic acid.

The anti-cellulite agent may, for example, be a xanthine compound, for example, an aminoporphyrin, caffeine, theophylline, theobromine or the like.

The above whitening agents may, for example, be nicotinic acid amide, citric acid, arbutin, glucosamine and derivatives, phytosterol derivatives, ascorbic acid and derivatives thereof, and mulberry extract and placenta extract.

Further, examples of the at least one other component include anti-inflammatory components, pH adjusters, antibacterial agents, moisturizers, perfumes, pigments, and dyes. Pigments, plant extracts, etc. The anti-inflammatory component may, for example, be a synthetic anti-inflammatory agent such as allantoin, di-potassium glycyrrhizinate, etc. derived from a natural anti-inflammatory agent such as peony, turmeric, small forsythia, chamomile, licorice, peach leaf, AI, and perilla extract. .

In the case of the above pH adjusting agent, the skin is kept weakly acidic, such as malic acid, succinic acid, citric acid, tartaric acid, lactic acid or the like.

The above pigment may, for example, be titanium oxide.

The blood modifying agent-containing composition is a blood modifying agent and at least one other component, and preferably contains from about 50 to about 99% by mass and from about 1 to about 50% by mass, more preferably from about 60 to about 99, respectively. % by mass and from about 1 to about 40% by mass, more preferably from about 70 to about 99% by mass and from about 1 to about 30% by mass, still more preferably from about 80 to about 99% by mass and from about 1 to about 20% by mass. More preferably, it is about 90 to 99% by mass and about 1 to about 10% by mass, and further preferably about 95 to 99% by mass and about 1 to about 5% by mass. It is considered from the viewpoint of the effects of the present invention.

It is preferable that the blood modifying agent contains a composition containing a surfactant having a hydrophilization treatment amount from the top sheet or the second sheet. More specifically, the blood modifying agent-containing composition preferably contains from about 0.0 to about 1.0 g/m ² , more preferably from about 0.0 to about 0.8 g/m ² , still more preferably from about 0.1 to about 0.5 g / M ² , and then more preferably a surfactant in the range of from about 0.1 to about 0.3 g/m ² .

When the amount of the surfactant increases, there is a tendency that the menstrual blood easily remains on the top sheet.

Moreover, in the case of surfactants, the technical field is generally available to users, for example An anionic surfactant, a cationic surfactant, a nonionic surfactant, an amphoteric surfactant, and the like.

The blood modifying agent contains a composition containing water preferably from about 0.0 to about 1.0 g/m ² , more preferably from about 0.0 to about 0.8 g/m ² , still more preferably from about 0.1 to about 0.5 g/m ² Further preferably, it is in the range of about 0.1 to about 0.3 g/m ² .

Water is less preferred because it lowers the absorption performance of the absorbent article.

When the blood modifying agent-containing composition contains a component which is a component of the at least one other component and the blood modifying agent, the other component preferably has a weight average molecular weight of less than 1,000, and more preferably has a weight. A weight average molecular weight of about 900. When the weight average molecular weight is about 1,000 or more, the composition of the blood modifying agent itself tends to be sticky, which tends to be unpleasant for the user. Further, since the weight average molecular weight is high, the viscosity of the composition of the blood modifying agent tends to increase, and it becomes difficult to reduce the viscosity of the composition of the blood modifying agent to a viscosity suitable for coating by heating, and as a result, it may occur. The blood modifying agent must be diluted with a solvent.

The above-mentioned liquid-permeable top sheet can be used without any particular limitation in the technical field, for example, a sheet-like material having a liquid-permeable structure, such as an apertured film, a woven fabric, a non-woven fabric, or the like. The fibers constituting the woven fabric and the non-woven fabric, for example, natural fibers and chemical fibers, and natural fibers, for example, pulverized cellulose such as pulp or cotton, and chemical fibers, for example, regenerated cellulose such as rayon or fibrillated rayon. Semi-synthetic cellulose such as acetate, triacetate, thermoplastic hydrophobic chemical fiber, And a hydrophilized thermoplastic thermoplastic fiber.

The thermoplastic hydrophobic chemical fiber may, for example, be a single fiber of polyethylene (PE), polypropylene (PP) or polyethylene terephthalate (PET), or a graft polymer of PE and PP. fiber.

Examples of the nonwoven fabric include, for example, a breathable nonwoven fabric, a spunbonded nonwoven fabric, a point-bonded nonwoven fabric, a water-flow woven nonwoven fabric, a needle-punched nonwoven fabric, a melt-blown nonwoven fabric, and the like (for example, SMS or the like).

The liquid-impermeable back sheet may, for example, be a film containing PE, PP or the like, a resin film having air permeability, a resin film having a gas permeable property such as a spun bond or a water flow entanglement, or a laminate layer of SMS or the like. Not weaving, etc. In view of the flexibility of the absorbent article, for example, a low density polyethylene (LDPE) film having a basis weight of from about 15 to about 30 g/m ² is preferred.

The liquid-impermeable back sheet has transparency in which the liquid diffusion length of the surface on the garment side of the absorbent body is visible to the user.

The second sheet may be, for example, a liquid permeable top sheet.

In the first example of the above-mentioned absorber, for example, the absorber core is covered with a core cladding.

The constituent elements of the above-mentioned absorption core may, for example, be semi-synthetic such as hydrophilic fibers, cellulose such as pulverized pulp or cotton, rayon, fibrillated rayon, or the like, regenerated cellulose, acetate, or triacetate. Cellulose, particulate polymer, fibrous polymer, thermoplastic hydrophobic chemical fiber, and hydrophilized thermoplastic chemical fiber treated with hydrophilization, and combinations thereof. Further, the constituent elements of the absorption core may be, for example, high absorption. A particulate material such as a polymer such as a sodium acrylate copolymer.

The core cladding layer is not particularly limited as long as it is liquid-permeable and has a barrier property that the polymer absorber is not permeable, such as woven fabric or non-woven fabric. Examples of the woven fabric and the non-woven fabric include natural fibers, chemical fibers, and woven fabrics.

The second example of the above-mentioned absorber may be, for example, an absorbent sheet or a polymer sheet, and preferably has a thickness of from about 0.3 to about 5.0 mm. In the absorbent sheet and the polymer sheet, the user of the absorbent article such as a sanitary napkin or the like can be used without any particular limitation.

Further, the blood modifying agent may be present in any position such as the entire top sheet and the central portion near the vaginal opening in the planar direction of the top sheet.

Further, when the liquid-permeable top sheet is formed of a non-woven fabric or a woven fabric, the blood modifying agent is preferably a void between fibers which does not block the nonwoven fabric or the woven fabric, and the blood modifying agent, for example, a fiber which can be woven. The surface is attached to the surface of the fiber in the form of droplets or particles. On the other hand, when the liquid permeable top sheet is formed of an apertured film, the blood modifying agent is preferably an opening which does not block the apertured film, and the blood modifying agent can be used, for example, on the surface of the apertured film. Attached in droplets or particles. When the blood modifying agent blocks the gap between the fibers of the nonwoven fabric or the woven fabric or the opening of the apertured film, the liquid that hinders the absorption moves to the absorber.

Further, in order to rapidly move the absorbed liquid, the blood modifying agent preferably has a large particle diameter and is preferably in the form of droplets or particles.

Further, in the first embodiment, the second sheet may contain a blood modifying agent. Further, in the first embodiment of the absorbent article, the absorbent body may contain a blood modifying agent.

In the above absorbent article, the top sheet contains the above blood modifying agent, preferably from about 1 to about 30 g/m ² , more preferably from about 2 to about 20 g/m ² , still more preferably from about 3 to about 10 g/m. The range of ² pings. When the amount of the blood modifying agent is less than about 1 g/m ² , the blood reforming effect tends to be insufficient. When the amount of the blood modifying agent increases, the sticky feeling in use tends to increase.

In the absorbent article of the present invention, the second sheet contains a ping of preferably from about 1 to about 30 g/m ² , more preferably from about 2 to about 20 g/m ² , still more preferably from about 3 to about 10 g/m ² . A quantity of blood modifying agent. When the amount of the above-mentioned amount is less than about 1 g/m ² , the blood reforming effect tends to be insufficient. When the amount is higher than about 30 g/m ² , for example, the materials such as the top sheet and the absorbent body are difficult to be heat-sealed. The tendency of the subsequent agent to join.

In the first embodiment of the absorbent article of the present invention, the absorbent body may contain the blood modifying agent. The absorbent body may contain an embodiment of a blood modifying agent, and the absorbent body preferably contains from about 1 to about 30 g/m ² , more preferably from about 2 to about 20 g/m ² , still more preferably from about 3 to about 10 g/m. ² of the amount of blood modifier. When the amount of the flatness is less than about 1 g/m ² , the blood reforming effect tends to be insufficient, and if it is higher than about 30 g/m ² , for example, the materials such as the second sheet and the back sheet become difficult to be heat-sealed. The tendency of the glue, the adhesive, etc. to join.

Moreover, the amount of the blood modifying agent of the top sheet is higher than that of the second sheet. The amount of liquid modifier is much better. The blood modifying agent is considered to be rapid in blood by changing the surface state of the top sheet and the second sheet, for example, changing the surface tension, so that the hydrophilic component (plasma, etc.) in the blood is not easily smeared on the top sheet and the second sheet. absorb. That is, the blood modifying agent has a low affinity with a hydrophilic component (plasma, etc.) in the blood, and has a tendency to repel blood to some extent. Therefore, by making the amount of the blood modifying agent of the second sheet smaller than the amount of the blood modifying agent of the top sheet, the blood passing through the top sheet can be rebounded to some extent, and the interface between the top sheet and the second sheet diffusion.

Further, in the absorbent article of the present invention, the total amount of the top sheet and the second sheet and the blood modifying agent according to the desired absorbent body is preferably from about 2 to about 60 g/m ² , more preferably about A blood modifying agent of from 3 to about 40 g/m ² , more preferably from about 4 to about 20 g/m ² . When the amount of the above-mentioned flatness is less than about 2 g/m ² , the blood reforming effect tends to be insufficient, and when the amount of the above-mentioned flatness exceeds about 60 g/m ² , the sticky feeling in use tends to increase.

Moreover, in the present specification, the amount of the blood modifying agent contained in the top sheet or the like can be measured as follows.

(1) The predicted range of the top sheet or the like is cut out by a sharp knife, for example, using a utility knife so as not to change its thickness as much as possible, and a sample is taken.

(2) Measuring the area of the sample: TS (m ² ) and mass: TW ₀ (g).

(3) The sample is immersed in a solvent capable of dissolving the blood modifying agent, such as ethanol, acetone or the like.

(4) The impregnated sample was dried in an oven at 60 °C.

(5) The mass of the sample after drying was measured: TW ₁ (g).

(6) The flatness BS (g/m ² ) of the blood modifying agent is expressed by the following formula: BS (g/m ² ) = [TW ₀ (g) - TW ₁ (g)] / TS (m ² ) * In order to reduce the error, a plurality of samples are taken from the plurality of absorbent articles in such a manner that the total area of the sample does not exceed 100 cm ² , and the experiments are repeated and the average values thereof are used.

The blood modifying agent may be present on the surface of the top sheet and/or the second sheet, or a blood modifying agent may be present, for example, inside the top sheet and/or the second sheet. Further, the absorbent body contains an embodiment of a blood modifying agent, and a blood modifying agent is preferably provided on the side of the skin.

Further, the top sheet and the second sheet may be the same as or different from the blood modifying agent possessed by the desired absorber.

When a material for applying a blood modifying agent is used, for example, when the top sheet is a non-woven fabric, a woven fabric or an apertured film made of a synthetic resin, it is preferred to apply a hydrophilic agent or to be hydrophilized by mixing. When the original material is hydrophilic, the lipophilic region and the hydrophilic region become sparsely coherent by applying a modifier having an organic IOC and a lipophilicity of about 0.00 to about 0.60. Therefore, it is considered that the menstrual blood composed of a hydrophilic component (plasma or the like) and a lipophilic component (such as blood cells) can exhibit a certain absorption performance.

The blood modifying agent or the blood modifying agent contains a composition as desired, and can be applied as a coating liquid containing a volatile solvent such as an alcohol solvent, an ester solvent, or an aromatic solvent. The coating liquid contains a volatile solvent, and the viscosity of the coating liquid containing the composition of the blood modifying agent or the blood modifying agent is lowered, so that the coating becomes easy, and it is not necessary to add it when coating is desired. The tempering of the coating step is simplified.

The method for applying the blood modifying agent or the blood modifying agent containing the composition or the coating liquid containing the same is not particularly limited, and the blood modifying agent or the blood modifying agent is required to contain the composition or the like. The coating liquid is heated, for example, using a non-contact type applicator, for example, a spiral applicator, a curtain coater, a spray applicator, a dip coater, etc., a contact applicator or the like The blood modifying agent or the blood modifying agent may be coated with a composition or a coating liquid containing the same. In the above coating apparatus, a non-contact type applicator is preferred from the viewpoint that the entire droplet-forming or particulate-shaped modifier is uniformly dispersed, and that the material is not damaged.

Further, the blood modifying agent or the blood modifying agent contains a composition or a coating liquid containing the same, and when it is a liquid at room temperature, it may be heated directly or decreased in viscosity, and then solid at room temperature. Heating is used to liquefy and can be applied by a controlled seam HMA (Hot Melt Adhesive) gun. By controlling the increase in the gas pressure of the joint HMA gun, a particulate-shaped blood modifying agent or a blood modifying agent-containing composition can be applied.

Further, the blood modifying agent or the blood modifying agent contains the coating amount of the composition, and can be adjusted, for example, by adjusting the amount of coating by the control joint HMA gun.

The blood modifying agent may be applied during the production of a material for the top sheet, for example, a non-woven fabric, or may be applied to a production line for producing an absorbent article. From the viewpoint of suppressing equipment investment, it is preferable to apply a blood modifying agent on the production line of the absorbent article, to prevent the blood modifying agent from falling off, and to contaminate the production line, in the downstream step of the production line, specifically before sealing the product into individual packaging. Preferably, the blood modifying agent is coated.

Where the blood modifying agent is applied immediately before sealing the product into individual packages, for example, a top sheet of an absorbent article precursor having a liquid permeable top sheet, a second sheet, an absorbent body, and a liquid impervious back sheet In the surface, the blood modifying agent is sprayed by the above-mentioned control seam HMA gun at a high gas pressure, for example, a pressure of about 0.5 MPa, and the blood can be modified once on the top sheet, the second sheet, and the desired absorber. Agent. By using a high gas pressure, the blood modifying agent can pass through the top sheet to the second sheet, and the desired absorbent body.

The above blood modifying agent may also function as a lubricant. When the top sheet is a non-woven fabric or a woven fabric, the friction between the fibers can be reduced, and the feeling of the non-woven fabric or the woven fabric can be improved. Further, when the top sheet is a resin film, the friction between the top sheet and the skin can be lowered.

The absorbent article is suitable for an absorbent article for absorbing blood, such as a sanitary napkin, a pad, or the like.

Further, the absorbent article of the present invention is different from the absorbent article containing the conventional care product composition, the emulsion composition, and the like, and does not require a component such as a buffering agent or an immobilizing agent, and may be a blood modifying agent monomer. Used in the top sheet and the second sheet.

Hereinafter, the present invention will be described by way of examples, but the invention is not limited thereto.

The blood modifying agents used in the experiments are listed below.

[(a ₁ ) an ester of a chain hydrocarbon tetraol with at least one fatty acid] ‧UNISTAR H-408BRS, manufactured by Nippon Oil Co., Ltd.

Tetrakilyl tetraethyl 4-hexyl carboxylate, weight average molecular weight: about 640

‧UNISTAR H-2408BRS-22, manufactured by Nippon Oil Co., Ltd.

Mixture of pentaerythritol tetraethyl 2-ethyl hexane acid and neopentyl glycol di 2-ethyl hexane acid (58:42, mass ratio), weight average molecular weight: about 520

[(a ₂ ) an ester of a chain hydrocarbon triol with at least one fatty acid] ‧Cetiol SB45DEO, made by Coguni Japan Stock Co., Ltd.

Fatty acid is glycerol and fatty acid triester of oleic acid or stearic acid

‧SOY42, made by Nippon Oil Co., Ltd.

Fatty acids containing C ₁₄ : C ₁₆ fatty acids: C ₁₈ fatty acids: C ₂₀ fatty acids (containing both saturated and unsaturated fatty acids) about 0.2:11:88:0.8 by mass ratio of glycerol to fatty acid triesters , weight average molecular weight: 880

‧Three C2L oil fatty acid glycerides, manufactured by Nippon Oil Co., Ltd.

Fatty acid containing C ₈ : fatty acid of C ₁₀ : fatty acid of C ₁₂ is about 37:7:56 by mass ratio of glycerol to fatty acid triester, weight average molecular weight: about 570

‧Three CL oil fatty acid glycerides, manufactured by Nippon Oil Co., Ltd.

Fatty acid containing C ₈ : fatty acid of C ₁₂ is about 44:56 by mass ratio of glycerol to fatty acid triester, weight average molecular weight: about 570

‧Panasate 810s, manufactured by Nippon Oil Corporation

Fatty acid containing C ₈ : C ₁₀ fatty acid about 85:15 by mass ratio of glycerol to fatty acid triester, weight average molecular weight: about 480

‧Panasate 800, made by Nippon Oil Co., Ltd.

Fatty acid is all octane acid (C ₈ ) glycerol and fatty acid triester, weight average molecular weight: about 470

‧Panasate 800B, made by Nippon Oil Co., Ltd.

The fatty acid is all 2-ethyl hexane acid (C ₈ ) glycerol and fatty acid triester, weight average molecular weight: about 470

‧NA36, made by Nippon Oil Co., Ltd.

Fatty acids containing C ₁₆ : C ₁₈ fatty acids: C ₂₀ fatty acids (containing both saturated and unsaturated fatty acids) about 5:92:3 by mass of glycerol and fatty acid triesters, weight average molecular weight: about 880

‧Three coconut oil fatty acid glycerides, manufactured by Nippon Oil Co., Ltd.

Fatty acids containing C ₈ : C ₁₀ fatty acids: C ₁₂ fatty acids: C ₁₄ fatty acids: C ₁₆ fatty acids (containing both saturated and unsaturated fatty acids) about 4:8:60:25:3 by mass ratio Triglyceride of glycerol and fatty acid, weight average molecular weight: 670

‧ Caprylic diglyceride, manufactured by Nippon Oil Co., Ltd.

The fatty acid is a diester of glycerol and fatty acid of octanoic acid, weight average molecular weight: 340

[(a ₃ ) ester of a chain hydrocarbon diol with at least one fatty acid] ‧Komubolu BL, made by Nippon Oil Co., Ltd.

Butyric acid (C ₁₂ ) monoester of butanediol, weight average molecular weight: about 270

‧Komu Bolu BS, made by Nippon Oil Co., Ltd.

Octadecanoic acid (C ₁₈ ) monoester of butanediol, weight average molecular weight: about 350

‧UNISTAR H-208BRS, manufactured by Nippon Oil Co., Ltd.

Diethyl 2-ethylhexane acid neopentyl glycol, weight average molecular weight: about 360

[(c ₂ ) an ester of a chain hydrocarbon tricarboxylic acid having three carboxyl groups, a hydroxy acid, an alkoxy acid or a pendant acid and at least one aliphatic monovalent alcohol] ‧O-Ethyl tributyl citrate, manufactured by Tokyo Chemical Industry Co., Ltd.

Weight average molecular weight: about 400

[(c ₃ ) an ester of a chain hydrocarbon dicarboxylic acid having two carboxyl groups, a hydroxy acid, an alkoxy acid or a pendant acid and at least one aliphatic monovalent alcohol] ‧Dioctyl adipate, manufactured by Wako Pure Chemical Industries

Weight average molecular weight: about 380

[(d ₃ ) ester of fatty acid with aliphatic monovalent alcohol] ‧Eliteru WE20, manufactured by Nippon Oil Co., Ltd.

Ester of dodecanoic acid (C ₁₂ ) and dodecyl alcohol (C ₁₂ ), weight average molecular weight: about 360

‧Eliteru WE40, made by Nippon Oil Co., Ltd.

Ester of tetradecanoic acid (C ₁₄ ) and dodecyl alcohol (C ₁₂ ), weight average molecular weight: about 390

[(e ₁ ) Polyoxygenated C ₃ ~C ₆ alkanediol] ‧Uniol PB500, manufactured by Nippon Oil Co., Ltd.

Polytetramethylene glycol, weight average molecular weight: about 500

‧Uniol PB700, manufactured by Nippon Oil Co., Ltd.

Polyoxybutylene polyoxypropylene glycol, weight average molecular weight: about 700

[(f ₁ )chain alkane] ‧Parleam 6, made by Nippon Oil Co., Ltd.

Copolymerization of flowing iso-liquid paraffin, isobutylene and n-butene, followed by hydrogenation of branched hydrocarbons, degree of polymerization: about 5 to about 10, weight average molecular weight: about 330

[other materials] ‧NA50, made by Nippon Oil Co., Ltd.

Adding hydrogen to NA36, reducing the ratio of glycerol to fatty acid triester from the ratio of unsaturated fatty acid double bonds of raw materials, weight average molecular weight: about 880

‧(octanoic acid/tannic acid) monoglyceride, manufactured by Nippon Oil Co., Ltd.

a monoester of glycerol and a fatty acid containing about 85:15 by mass of octanoic acid (C ₈ ) and decanoic acid (C ₁₀ ), weight average molecular weight: about 220

‧Monomuls 90-L2 lauric acid monoglyceride, manufactured by Coguni Japan Co., Ltd. ‧Isopropyl citrate, manufactured by Tokyo Chemical Industry Co., Ltd.

Weight average molecular weight: about 230

‧ Malate diisostearyl methacrylate

Weight average molecular weight: about 640

‧Uniol PB1000R, manufactured by Nippon Oil Co., Ltd.

Polytetramethylene glycol, weight average molecular weight: about 1,000

‧Uniol D-400, manufactured by Nippon Oil Co., Ltd.

Polypropylene glycol, weight average molecular weight: about 400

‧Uniol D-1000, manufactured by Nippon Oil Co., Ltd.

Polypropylene glycol, weight average molecular weight: about 1,000

‧Uniol D-1200, manufactured by Nippon Oil Co., Ltd.

Polypropylene glycol, weight average molecular weight: about 1,160

‧Uniol D-3000, manufactured by Nippon Oil Co., Ltd.

Polypropylene glycol, weight average molecular weight: about 3,000

‧Uniol D-4000, manufactured by Nippon Oil Co., Ltd.

Polypropylene glycol, weight average molecular weight: about 4,000

‧PEG1500, made by Nippon Oil Co., Ltd.

Polyethylene glycol, weight average molecular weight: about 1,500 ~ about 1,600

‧WILBRIDE cp9, made by Nippon Oil Co., Ltd.

a compound in which the OH groups at both ends of polytetramethylene glycol are esterified with palmitic acid (C ₁₆ ), weight average molecular weight: about 1,150

‧UNILUBE MS-70K, manufactured by Nippon Oil Co., Ltd.

Stearic acid decyl ether of polypropylene glycol, about 15 repeating units, weight average molecular weight: about 1,140

‧NONION S-6, made by Nippon Oil Co., Ltd.

Polyoxyethylene monostearate, about 7 repeat units, weight average Molecular weight: about 880

‧UNILUBE 5TP-300KB

A polyoxyethylene polyoxypropylene pentaerythritol ether formed by adding pentaerythritol 1 molar to ethylene oxide 5 moles and propylene oxide 65 moles, weight average molecular weight: 4,130

‧WILBRIDE s753, manufactured by Nippon Oil Co., Ltd.

Polyoxyethylene polyoxypropylene polyoxybutylene glycerol, weight average molecular weight: about 960

‧Uniol TG-330, manufactured by Nippon Oil Co., Ltd.

Glyceryl ether of polypropylene glycol, repeating unit of about 6, weight average molecular weight: about 330

‧Uniol TG-1000, manufactured by Nippon Oil Co., Ltd.

Glyceryl ether of polypropylene glycol, about 16 repeating units, weight average molecular weight: about 1,000

‧Uniol TG-3000, manufactured by Nippon Oil Co., Ltd.

Glyceryl ether of polypropylene glycol, about 16 repeating units, weight average molecular weight: about 3,000

‧Uniol TG-4000, manufactured by Nippon Oil Co., Ltd.

Glyceryl ether of polypropylene glycol, about 16 repeating units, weight average molecular weight: about 4,000

‧UNILUBE DGP-700, manufactured by Nippon Oil Co., Ltd.

Diglyceryl ether of polypropylene glycol, repeating unit of about 9, weight average molecular weight: about 700

‧uniox HC60, manufactured by Nippon Oil Co., Ltd.

Polyoxyethylene hardened castor oil, weight average molecular weight: about 3,570

‧Vaseline, Koguni Japan Co., Ltd.

Hydrocarbon, semi-solid from petroleum

[example 1] [Liquid Drop Test]

Prepare a breathable non-woven fabric treated with a hydrophilic agent (a composite fiber having a polyethylene terephthalate and a sheath as a polyester, a fineness of 2.8 dt, a core containing 4% by mass of titanium oxide, and a basis weight of 25 g/m ² ) A top sheet (hereinafter abbreviated as "TS"), a second sheet (hereinafter referred to as "SS") formed of a permeable nonwoven fabric similar to the top sheet, and an absorbent body (short amount of 300 g/m ² ) The fine pulp was rubbed with two sheets of fabric having a basis weight of 14 g/m ² , pressed into an absorbent body having a density of 0.1 g/cm ³ and a thickness of 3.0 mm, and a back sheet formed of a polyethylene film.

Next, the initial quality (material quality) of the top sheet and the second sheet was measured.

Panathate 810s (IOB: 0.32, melting point: -5 ° C, water solubility: <0.05) as a blood modifying agent, at room temperature, by the control joint HMA gun on the skin contact surface of the top sheet (mud surface) It was coated at a basis weight of 3 g/m ² . It was confirmed by electron microscopy that Panasate 810s adhered to the surface of the fibers in the form of fine particles. Next, in the same manner, Panaseate 810s was applied to the skin contact surface side of the second sheet at a basis weight of 2 g/m ² .

Next, the back sheet, the absorbent body, the second sheet, and the top sheet are sequentially overlapped with the coating surface of the blood modifying agent, and clamped by the clip In a few places, a sanitary napkin No. 1-1 was formed.

The type and the amount of the blood modifying agent applied to the surface of the top sheet, the second sheet, and the absorbent body were changed as described in the following Table 2, and the same manner as the method of forming the sanitary napkin No. 1-1. Forming sanitary napkin No. 1-2~1-6.

Further, in the sanitary napkin No. 1-3 in which the absorbent body was coated with the blood modifying agent, in the same manner as in the case of the top sheet, Panaseate 810s was applied at a basis weight of 1 g/m ² , and the absorbent body was coated. The cloth faces up with other materials to form an absorbent article. Further, in Table 2, when the amount of the blood modifying agent is described as 0, it means that the blood modifying agent is not applied.

The liquid dropping test was carried out in accordance with the procedure described in the present specification, and the liquid residual ratio and the liquid diffusion length of the sanitary napkin No. 1-1 to 1-6 were evaluated. The results are shown in Table 2.

The sanitary napkin No. 1-1 to 1-3 has almost no menstrual blood in both the top sheet and the second sheet, and the liquid diffusion length ratio TS of the absorber side (the side of the coating side of the absorber) The liquid diffusion length of the side (the skin contact surface of the top sheet) is long, so the user is in the absorbent article. When changing, it can be seen that the absorbent article absorbs menstrual blood, and the menstrual blood remains in the inside of the absorbent body, and a feeling of relief is obtained.

Physiological cotton No. 1-1 to 1-6 are used for a plurality of subjects, and No. 1-1 to 1-3 are compared with No. 1-4 to 1-6, especially No. 1-6. In comparison, when the absorbent article is replaced, it can be confirmed that the absorbent article absorbs menstrual blood and menstrual blood and remains inside the absorbent body to obtain a feeling of relief.

[Example 2] [Evaluation of the rate of rewet, the speed of movement of the absorbent body, the whiteness of the skin contact surface of the top sheet, and the amount of residual blood]

Prepare commercially available sanitary napkins. The sanitary tampon is a top sheet formed by a hydrophilic agent-treated permeable non-woven fabric (composite fiber composed of polyester and polyethylene terephthalate, and a flat weight: 35 g/m ² ), and a permeable non-woven fabric (polymerized) a composite fiber made of ester and polyethylene terephthalate, a flat sheet of 30 g/m ² ), a pulp (powder: 150-450 g/m ² , more central portion), An acrylic-based superabsorbent polymer (ply: 15 g/m ² ) and an absorbent body of a fabric as a core cladding, a water-repellent-treated side sheet, and a back sheet formed of a polyethylene film.

The IOB of the above sample, the melting point, the water solubility, and the weight average molecular weight are shown in Table 3 below.

Further, the water solubility was measured by the above method, and 20.0 g of 100 g of demineralized water was added, and the sample dissolved after 24 hours was evaluated as "20 g <", followed by dissolution of 0.05 g in 100 g of demineralized water, but did not dissolve 1.00. g The sample was evaluated to be 0.05 to 1.00 g.

Also, regarding the melting point, "<45" means that the melting point is less than 45 °C.

The skin contact surface of the top sheet of the above sanitary napkin is coated with the above blood modifying agent. Each blood modifying agent is directly applied to the blood modifying agent at room temperature, and then the blood modifying agent is heated to a melting point of +20 ° C when the room temperature is solid. Then, using a control seam HMA gun, each The blood modifying agent was micronized, and the entire skin contact surface of the top sheet was applied so as to have a basis weight of about 5 g/m ² .

In Example 2, the range of the top sheet containing the blood modifying agent is as shown in FIG. As shown in Fig. 1, in the example 2, the top sheet 2 of the sanitary napkin 1 is almost entirely a blood modifying agent containing region 4 containing a blood modifying agent. In addition, in FIG. 1, the code|symbol 3 is a press part.

Fig. 2 is an electron micrograph of the skin contact surface of the top sheet of the physiological sanitary napkin (No. 5) containing the top C 3L oil fatty acid glyceride. As can be seen from Fig. 2, the tri-C2L oil fatty acid glyceride is in the form of fine particles and is present on the surface of the fiber.

[Test Method - Return Rate and Movement Rate of Absorber]

On the top sheet containing each blood modifying agent, an open acrylic plate (200 mm × 100 mm, 125 g, a hole of 40 mm × 10 mm in the center) was placed, and the horse was EDTA blood (the blood of the horse at 37 ± 1 ° C) from the above hole. In order to prevent coagulation, 3.0 g of ethylenediaminetetraacetic acid (hereinafter referred to as "EDTA") was added, and it was dropped using a pipette (first time), and after 1 minute, 37 ± 1 °C horse EDTA blood was added. 3.0g is dropped from the pore of the acrylic plate by the pipette (2nd).

Immediately after the dropping of the second blood, the acrylic plate was removed, and 10 pieces of filter paper (ADVANTEC Toyo Co., Ltd. qualitative filter paper No. 2, 50 mm × 35 mm) were placed in the place where the blood was dropped (the total mass of 10 pieces of filter paper: FW) ₀ (g)), a weight was placed from the above to make the pressure 30 g/cm ² . After 1 minute, the filter paper was taken out, and the total mass FW ₁ (g) of 10 pieces of filter paper after the test was measured, and the "reverse bleed rate" was calculated by the following formula.

Infiltration rate (% by mass) = 100 × [FW ₁ (g) - FW ₀ (g)] / 6.0 (g)

Further, in addition to the evaluation of the rewet rate, after the second blood drop, the time during which the blood was moved from the top sheet to the absorber, that is, the "absorbent moving speed" was measured. The moving speed of the absorbent body refers to the time from when the blood is put into the absorbent body until the red color of the blood is not visible on the surface and inside of the top sheet.

The results of the infiltration rate and the moving speed of the absorbent body are shown in Table 3.

[Test method - whiteness of the skin contact surface of the top sheet]

The whiteness of the skin contact surface of the top sheet after the test of the moving speed of the absorbent body was visually evaluated based on the following criteria.

◎: The red color of blood hardly remains, and it is impossible to distinguish between the place where blood exists and the place where it does not exist.

○: Although the red color of the blood remains slightly, the place where the blood exists is not easily distinguished from the place where it does not exist.

△: A place where the red color of the blood remains, and the blood can be distinguished.

×: Red red residue of blood

The results are shown in Table 3.

[Test method - residual blood volume]

In addition to changing the amount of EDTA blood dropped to 4.0 g, according to the operation of the liquid dropping test described above, the amount of remaining blood (g) is represented by the following formula: residual blood amount (g) = quality of the material after the test (g) - The quality of the materials (g) was calculated.

The results are shown in Table 3.

Table 3 shows an example in which the top sheet has a blood modifying agent, but the second sheet does not have a blood modifying agent, and it is known that it has an IOB of about 0.00 to about 0.60, a melting point of about 45 ° C or less, and a water of about 100 ° C of about 0.00 °. A blood modifying agent having a water solubility of about 0.05 g and a weight average molecular weight of less than 1,000 has the same rewet ratio, absorbent moving speed, and residual blood amount as Panaset 810s.

Therefore, the top sheet and the second sheet have a water solubility of from about 0.00 to about 0.60 IOB, a melting point of about 45 ° C or less, a water content of from about 0.00 to about 0.05 g to 100 g of water at 25 ° C, and a weight average of less than 1,000. In the case of a molecular weight blood modifying agent, the absorbed menstrual blood can be rapidly moved and diffused to the absorbent body in the same manner as Panasate 810s. Therefore, in the liquid dropping test described in the present specification, the liquid residual ratio of the top sheet and the second sheet is obtained. The liquid diffusion length in the longitudinal direction of the absorbent article of 3.0% by mass or less and the skin contact surface of the top sheet is shorter than the liquid diffusion length in the longitudinal direction of the absorbent article on the garment side of the absorbent body.

Further, when the blood modifying agent having a weight average molecular weight of about 1,000 or more is excellent in the rewet ratio, the moving speed of the absorbent body, and the amount of residual blood, it is not preferable from the viewpoint of stickiness. I feel sticky when I use it.

In addition, the physiological sanitary napkins of No. 2-1 to 2-47 are used for a plurality of volunteers, and the physiological sanitary napkin containing the blood modifying agent of No. 2-1 to 2-22 is obtained. Even after absorbing menstrual blood, the top sheet has no sticky feeling and the top sheet is dry.

In addition, the physiological sanitary napkins of No. 2-1 to No. 2-22 include the physiology of blood modifying agents No. 2-1 to 2-11, 2-15 to 2-19, and 2-22. use In the sanitary napkin, the skin contact surface of the top sheet obtained by the menstrual blood is not stained with blood by the blood, and the answer is unpleasant.

[Example 3]

Regarding the various blood of the animals, the rate of rewet was evaluated in accordance with the above sequence. The blood used in the experiment is as follows.

[Animal species]

(1 person

(2) Horse

(3) sheep

[blood type]

‧Defibration: After taking blood, stirring with glass beads in a conical flask for about 5 minutes

‧EDTA blood: Add 12% EDTA to venous blood 65mL. 2K physiological saline solution 0.5mL

[Division]

Serum or plasma: supernatant from which defibrinated blood or EDTA blood is separately centrifuged at about 1900 G for 10 minutes at room temperature

Blood cells: serum is removed from the blood, and the residue is washed twice with phosphate buffered physiological saline solution (PBS), followed by addition of the removed serum to the phosphate buffered physiological saline solution.

An absorbent article was produced in the same manner as in Example 2 except that the amount of the C2L oil fatty acid glyceride was about 5 g/m ² , and the rewet ratio was evaluated for each of the above blood. Each blood was measured three times, and the average value was used.

The results are shown in Table 4 below.

The same tendency as the horse EDTA blood obtained in Example 2 was also obtained in the blood of humans and sheep. Also, the same tendency was observed in defibrinated blood and EDTA blood.

[Example 4] [Evaluation of blood retention]

The blood retention in the top sheet containing the blood modifying agent and the top sheet containing no blood modifying agent was evaluated.

[experiment method]

(1) The skin contact surface of the top sheet formed by the permeable non-woven fabric (composite fiber composed of polyester and polyethylene terephthalate, and the basis weight: 35 g/m ² ) is used for the tri-C2L oil fatty acid glyceride. The control joint HMA gun was micronized and applied in such a manner that the basis weight became about 5 g/m ² . Further, for comparison, those who do not apply the tri-C2L oil fatty acid glyceride are also prepared. Next, both the top sheet coated with the tri-C2L oil fatty acid glyceride and the uncoated top sheet were cut to a size of 0.2 g, and the mass a (g) of the sterile cell filtration cap tube + top sheet was correctly measured.

(2) About 2 mL of horse EDTA blood was added from the skin contact surface side, and allowed to stand for 1 minute.

(3) The sterile cell filtration cap tube was placed in a centrifuge tube, and subjected to low-speed centrifugation to remove excess horse EDTA blood.

(4) The weight b (g) of the top sheet containing the sterile cell filter cap + horse EDTA blood was measured.

(5) The initial absorption amount (g) per 1 g of the top sheet was calculated according to the following formula.

Initial absorption (g) = [b(g) - a(g)] / 0.2 (g)

(6) The sterile cell filtration cap tube was further placed in a centrifuge tube, and centrifuged at about 1200 G for 1 minute at room temperature.

(7) The weight c (g) of the top sheet containing the sterile cell filter cap + horse EDTA blood was measured.

(8) Calculate the amount of absorption per 1 g of the top sheet according to the following formula (g).

Absorption after test (g) = [c(g)-a(g)]/0.2(g)

(9) The blood retention rate (% by mass) was calculated according to the following formula.

Blood retention rate (% by mass) = 100 × absorption after test (g) / initial absorption (g)

Further, the measurement was carried out three times, and the average value thereof was used.

The results are shown in Table 5 below.

It can be seen that the top sheet containing the blood modifying agent has low blood retention and can quickly move to the absorber after absorbing blood.

[Example 5] [Voice of blood containing blood modifying agent]

The viscosity of blood containing a blood modifying agent was measured using a Rheometric Expansion System ARES (Rheometric Scientific, Inc). 2% by mass of Panasate 810s was added to the horse-depleted blood, and the sample was gently stirred to form a sample, and the sample was placed on a plate having a diameter of 50 mm with a gap of 100 μm, and the viscosity was measured at 37 ± 0.5 °C. Because of the flat plate, although the uniform shear rate was not applied to the sample, the average shear rate indicated by the machine was 10 s ^-1 .

The viscosity of equine defibrinated blood containing 2% by mass of Panasate 810s is 5.9 mPa. s, on the other hand, the viscosity of the horse blood fiber without the blood modifier It is 50.4 mPa. s. Therefore, it was found that the horse-defibrinated blood containing 2% by mass of Panasate 810s had a viscosity of about 90% lower than that of the case without the blood modifying agent.

The blood is known to contain components such as blood cells and has a property of shaking, but it is considered that the blood modifying agent of the present invention lowers the viscosity of blood in a low viscosity domain. It is believed that by reducing the viscosity of the blood, the absorbed menstrual blood can be quickly moved from the top sheet to the absorber.

[Example 6] [Micrograph of blood containing blood modifying agent]

The menstrual blood of the healthy volunteers was collected on the wrap film, and Panastate 810s dispersed in 10 times by mass of phosphate buffered physiological saline was added in such a manner that the concentration of Panaseate 810s was 1% by mass. The menstrual blood was dripped onto the slide glass, and the coverslip was covered, and the state of the red blood cells was observed with an optical microscope. A micrograph of the menstrual blood containing no blood modifying agent is shown in Fig. 3(a), and then a micrograph of the menstrual blood containing Panasate 810s is shown in Fig. 3(b).

As can be seen from Fig. 3, in the menstrual blood containing no blood modifying agent, a collecting block in which red blood cells are continuously arranged is formed, but in the menstrual blood containing Panasate 810s, the red blood cells are stably dispersed. Therefore, it is understood that the blood modifying agent has an effect of stabilizing the red blood cells in the blood.

[Example 7] [Surface tension of blood containing blood modifying agent]

The surface tension of the blood containing the blood modifying agent was measured by a drip method using a contact angle meter Drop Master 500 manufactured by Kyowa Interface Science Co., Ltd. The surface tension is applied to the sheep defibrinated blood, and a specific amount of the blood modifying agent is added and measured after shaking sufficiently.

The measurement was automatically performed by a machine, and the surface tension γ was obtained by the following equation (see Fig. 8 for reference).

γ =g× ρ ×(de) ² ×1/H

g: gravity constant

1/H: correction term determined by ds/de

ρ : density

De: maximum diameter

Ds: the diameter of the position where only the de is raised by the drop end

The density ρ is measured according to the vibration density test method of "Density Test Method and Density ‧ Mass ‧ Capacity Conversion Table" of JIS K 2249-1995, and is measured at the temperature shown in Table 6 below.

The measurement was performed using DA-505 of Kyoto Electronics Industry Co., Ltd.

The results are shown in Table 6.

As can be seen from Table 6, the blood modifying agent has a water solubility of about 0.00 to 0.05 g per 100 g of water at 25 ° C. It is also understood that although the water solubility is very low, the surface tension of blood can be lowered.

It is considered that by lowering the surface tension of blood, the absorbed blood does not remain between the fibers of the top sheet, and can be quickly moved to the absorber.

The present invention relates to the following J1 to J12.

[J1]

An absorbent article comprising a liquid permeable top sheet, an absorbent body, a liquid impermeable back sheet, an absorbent article of the top sheet and a second sheet between the absorbent members, characterized in a liquid dripping test [1] The liquid remaining ratio of the top sheet and the second sheet is 3.0% by mass or less, and then [2] the liquid diffusion length in the longitudinal direction of the absorbent article of the skin contact surface of the top sheet is higher than that of the absorbent body. The liquid diffusion length in the longitudinal direction of the side absorbent article is short.

[J2]

The absorbent article according to J1, wherein, in the liquid dripping test, [3] the liquid diffusion length in the width direction of the absorbent article of the skin contact surface of the top sheet is larger than the absorbent article on the garment side of the absorbent body. The liquid diffusion length in the width direction is short.

[J3]

The absorbent article according to J1, wherein the top sheet and the second sheet contain an IOB having a thickness of 0.00 to 0.60 and a melting of 45 ° C or less. 100 g of water at 25 ° C is a water modifier having a water solubility of about 0.00 to 0.05 g and a weight average molecular weight of less than 1,000.

[J4]

The absorbent article according to J3, wherein the blood modifying agent is selected from the group consisting of (i) to (iii), (i) hydrocarbon, (ii) having (ii-1) hydrocarbon portion, and (ii-2) a compound inserted between the CC single bonds of the hydrocarbon moiety, one or a plurality of identical or different groups selected from the group consisting of a carbonyl group (-CO-) and an oxy group (-O-), and (iii) One or plural selected from the group consisting of a carbonyl group (-CO-) and an oxy group (-O-), having (iii-1) a hydrocarbon moiety and (iii-2) inserted between the CC single bonds of the hydrocarbon moiety One or a plurality of identical or different groups selected from the group consisting of a hydrogen atom, a carboxyl group (-COOH) and a hydroxyl group (-OH) substituted with the aforementioned hydrocarbon moiety; In the group of the compound and any combination thereof, and in the compound of (ii) or (iii), when two or more oxy groups are inserted, each oxy group is not adjacent.

[J5]

The absorbent article according to J3 or J4, wherein the blood modifying agent is selected from the group consisting of (i') to (iii'), (i') hydrocarbon, and (ii') having (ii'-1) hydrocarbon. Part, and (ii'-2) inserted between the CC single bond of the aforementioned hydrocarbon moiety, carbonyl bond (-CO-), ester bond (-COO-), carbonate bond (-OCOO-), and ether Bonding (-O-) in groups One or more of the same or different bonded compounds selected, and (iii') having a (iii'-1) hydrocarbon moiety, and (iii'-2) intercalated between the CC single bonds of the hydrocarbon moiety, a carbonyl group One or a plurality of identical or different selected from the group consisting of a bond (-CO-), an ester bond (-COO-), a carbonate bond (-OCOO-), and an ether bond (-O-) a bond, and (iii'-3) a compound substituted with one or a plurality of the same or different groups selected from the group consisting of a hydrogen atom of the hydrocarbon moiety, a carboxyl group (-COOH), and a hydroxyl group (-OH), and In the group of any combination of these, in the case of the compound of (ii') or (iii'), when two or more identical or different bonds are inserted, the bonds are not adjacent.

[J6]

The absorbent article according to any one of the present invention, wherein the blood modifying agent is selected from the group consisting of the following (A) to (F), (A) (A1) having a chain hydrocarbon moiety, and substituting the chain a compound having 2 to 4 hydroxyl groups of a hydrogen atom in a hydrocarbon portion, an ester having a chain hydrocarbon moiety (A2), and a compound having a carboxyl group substituted for a hydrogen atom of the chain hydrocarbon moiety, (B) ( B1) a compound having a chain hydrocarbon moiety and a hydroxyl group of 2 to 4 atoms which replaces the hydrogen atom of the chain hydrocarbon moiety, and (B2) having a chain hydrocarbon moiety and a hydrogen atom replacing the chain hydrocarbon moiety a hydroxyl group-containing compound ether, (C) (C1) containing a chain hydrocarbon moiety, and a carboxylic acid, a hydroxy acid, an alkoxy acid or a carboxy group substituted with 2 to 4 carboxyl groups of a hydrogen atom of the aforementioned chain hydrocarbon moiety a side oxyacid, an ester having a chain hydrocarbon moiety (C2), a compound having a hydroxyl group substituted for one hydrogen atom of the chain hydrocarbon moiety, (D) having a chain hydrocarbon moiety, and being inserted into the chain The CC bond between the hydrocarbon moiety is grouped by an ether bond (-O-), a carbonyl bond (-CO-), an ester bond (-COO-), and a carbonate bond (-OCOO-). The combination of any one of the selected bonds The group of (E) polyoxygenated C ₃ -C ₆ alkanediol, or the alkyl or alkyl ether, and (F) chain hydrocarbon, and any combination thereof are selected.

[J7]

The absorbent article according to any one of the above items, wherein the blood modifying agent is an ester of (a ₁ ) a chain hydrocarbon tetraol with at least one fatty acid, (a ₂ ) a chain hydrocarbon triol An ester of at least one fatty acid, an ester of (a ₃ ) a chain hydrocarbon diol and at least one fatty acid, (b ₁ ) a chain hydrocarbon tetraol, and an ether of at least one aliphatic monovalent alcohol, ( b ₂ ) an ether of a chain hydrocarbon triol with at least one aliphatic monovalent alcohol, (b ₃ ) a chain hydrocarbon diol, and an ether of at least one aliphatic monovalent alcohol, (c ₁ ) having 4 a chain hydrocarbon tetracarboxylic acid, a hydroxy acid, an alkoxy acid or a pendant acid ester of a carboxyl group and an ester of at least one aliphatic monovalent alcohol, (c ₂ ) a chain hydrocarbon tricarboxylic acid having three carboxyl groups, An ester of a hydroxy acid, an alkoxy acid or a pendant acid with at least one aliphatic monovalent alcohol, (c ₃ ) a chain hydrocarbon dicarboxylic acid having two carboxyl groups, a hydroxy acid, an alkoxy acid or a side An ester of an oxyacid with at least one aliphatic monovalent alcohol, (d ₁ ) an aliphatic monovalent alcohol and an aliphatic monovalent alcohol ether, (d ₂ ) dialkyl ketone, (d ₃ ) fatty acid and fat An ester of a monovalent alcohol, (d ₄ ) dialkyl carbonate, (e ₁ ) polyoxy C ₃ ~ C ₆ alkanediol, (e ₂ ) polyoxygen An ester of a C ₃ -C ₆ alkanediol with at least one fatty acid, (e ₃ ) a polyoxy C ₃ -C ₆ alkanediol and an ether of at least one aliphatic monovalent alcohol, and (f ₁ ) A group of linear alkanes, and any combination thereof, is selected.

[J8]

The absorbent article according to any one of the above-mentioned, wherein the amount of the blood modifying agent of the top sheet is larger than the amount of the blood modifying agent of the second sheet.

[J9]

The absorbent article according to any one of the above aspects, wherein the absorbent body further contains the blood modifying agent on a side surface of the skin.

[J10]

The absorbent article according to any one of the above-mentioned, wherein the liquid-permeable top sheet and/or the second sheet is a non-woven fabric or a woven fabric, and the blood modifying agent is attached to the non-woven fabric or the woven fabric. Fiber surface.

[J11]

An absorbent article according to any one of J1 to J10, which is a sanitary napkin or a pad.

[J12]

The absorbent article according to any one of the items J1 to J11, wherein the liquid permeable top sheet, the absorbent body, the liquid impervious back sheet, the liquid permeable top sheet, and the absorbent body are provided. The second sheet of the absorbent article precursor is produced by spraying the blood modifying agent from the liquid permeable top sheet side.

1‧‧‧Physical sanitary napkins

2‧‧‧Top sheet

3‧‧‧Squeeze Department

4‧‧‧ Blood Modifier Containing Area

Fig. 1 is a view showing a range in which a top sheet contains a blood modifying agent in Example 2.

Fig. 2 is an electron micrograph of the skin contact surface of the top sheet of the physiological sanitary napkin containing the top C 3L oil fatty acid glyceride.

Fig. 3 is a photomicrograph of menstrual blood with or without a blood modifying agent.

Fig. 4 is a view for explaining a method of measuring surface tension.

Claims (12)

An absorbent article comprising a liquid permeable top sheet, an absorbent body, a liquid impermeable back sheet, an absorbent article of the top sheet and a second sheet between the absorbent members, characterized in a liquid dripping test [1] The liquid remaining ratio of the top sheet and the second sheet is 3.0% by mass or less, and then [2] the liquid diffusion length in the longitudinal direction of the absorbent article of the skin contact surface of the top sheet is higher than that of the absorbent body. The liquid diffusion length in the longitudinal direction of the side absorbent article is short, and the top sheet and the second sheet contain an IOB of 0.00 to 0.60, a melting point of 45 ° C or less, and a water of 100 g of 25 ° C of 0.00 to 0.05 g. A water modifying agent for water solubility. The absorbent article according to claim 1, wherein in the liquid dropping test, [3] the liquid diffusion length in the width direction of the absorbent article of the skin contact surface of the top sheet is higher than the absorption side of the coating body of the absorbent body. The liquid diffusion length in the width direction of the sexual article is short. The absorbent article according to claim 1 or 2, wherein the blood modifying agent has a weight average molecular weight of less than 1,000. The absorbent article according to claim 1 or 2, wherein the blood modifying agent is selected from the group consisting of (i) to (iii) and any combination thereof, (i) hydrocarbon, (ii) ) having (ii-1) a hydrocarbon moiety and (ii-2) inserted in the aforementioned hydrocarbon a compound of one or a plurality of identical or different groups selected from a group consisting of a carbonyl group (-CO-) and an oxy group (-O-), and (iii) having (iii-1) a hydrocarbon moiety, one or a plurality of the same or different from the group consisting of a carbonyl group (-CO-) and an oxy group (-O-) interposed between the CC single bond of the hydrocarbon moiety (iii-2) And a compound of one or more of the same or different groups selected from the group consisting of a carboxyl group (-COOH) and a hydroxyl group (-OH) in place of the hydrogen atom of the hydrocarbon moiety (iii-3), and (iii-3) In the compound of ii) or (iii), when two or more oxy groups are inserted, each oxy group is not adjacent. The absorbent article according to claim 1 or 2, wherein the blood modifying agent is selected from the group consisting of (i') to (iii') and any combination thereof, (i') hydrocarbon And (ii') a carbonyl bond (-CO-) or an ester bond (-COO-) having a (ii'-1) hydrocarbon moiety and (ii'-2) inserted between the CC single bonds of the hydrocarbon moiety. a compound selected from the group consisting of carbonate linkage (-OCOO-) and ether linkage (-O-), or a plurality of identical or different bonded compounds, and (iii') having (iii' -1) a hydrocarbon moiety, and (iii'-2) inserted between the CC single bond of the aforementioned hydrocarbon moiety by a carbonyl bond (-CO-), an ester bond (-COO-), a carbonate bond (-OCOO) -), and one or more of the same or different linkages selected from the group of ether linkages (-O-), and a carboxyl group (-COOH) substituted with (iii'-3) a hydrogen atom of the aforementioned hydrocarbon moiety And one or more of the same or different ones selected from the group consisting of hydroxyl groups (-OH) Herein, in the compound of (ii') or (iii'), when two or more identical or different bonds are inserted, each bond is not adjacent. The absorbent article according to claim 1 or 2, wherein the blood modifying agent is selected from the group consisting of the following (A) to (F) and any combination thereof, and (A) (A1) has a chain hydrocarbon portion, a compound having 2 to 4 hydroxyl groups substituted for a hydrogen atom of the chain hydrocarbon portion, a carboxyl group having (A2), and a carboxyl group replacing a hydrogen atom of the chain hydrocarbon portion The ester of the compound, (B) (B1) having a chain hydrocarbon moiety, a compound having 2 to 4 hydroxyl groups substituted for the hydrogen atom of the chain hydrocarbon moiety, (B2) having a chain hydrocarbon moiety, and substituting the aforementioned An ether of a compound having one hydroxyl group of a hydrogen atom in a chain hydrocarbon portion, (C) (C1), a chain hydrocarbon portion, and a carboxylic acid having 2 to 4 carboxyl groups which replace a hydrogen atom of the chain hydrocarbon portion, An ester of a hydroxy acid, an alkoxy acid or a pendant acid, a compound having a chain hydrocarbon moiety (C2), a hydroxyl group substituted for a hydrogen atom of the aforementioned chain hydrocarbon moiety, and (D) a chain hydrocarbon Partly, an ether bond (-O-), a carbonyl bond (-CO-), an ester bond (-COO-), and a carbonate bond (between the CC single bond inserted into the aforementioned chain hydrocarbon moiety) -OCOO-) group Any one of the selected compounds, (E) a polyoxy C ₃ -C ₆ alkanediol, or the alkyl or alkyl ether, and (F) a chain hydrocarbon. The absorbent article according to claim 1 or 2, wherein the blood modifying agent is an ester of (a ₁ ) a chain hydrocarbon tetraol with at least one fatty acid, (a ₂ ) a chain hydrocarbon triol, and at least An ester of one fatty acid, an ester of (a ₃ ) chain hydrocarbon diol and at least one fatty acid, (b ₁ ) a chain hydrocarbon tetraol, and an ether of at least one aliphatic monovalent alcohol, (b ₂ An ether of a chain hydrocarbon triol with at least one aliphatic monovalent alcohol, (b ₃ ) a chain hydrocarbon diol and an ether of at least one aliphatic monovalent alcohol, and (c ₁ ) having 4 carboxyl groups An ester of a chain hydrocarbon tetracarboxylic acid, a hydroxy acid, an alkoxy acid or a pendant acid with at least one aliphatic monovalent alcohol, (c ₂ ) a chain hydrocarbon tricarboxylic acid having three carboxyl groups, a hydroxy acid An ester of an alkoxy acid or a pendant acid with at least one aliphatic monovalent alcohol, (c ₃ ) a chain hydrocarbon dicarboxylic acid having two carboxyl groups, a hydroxy acid, an alkoxy acid or a pendant oxy group acid and at least one aliphatic ester of a monovalent alcohol, (d ₁₎ a monovalent aliphatic alcohol with a monovalent aliphatic alcohol of an ether, (d ₂₎ dialkyl ketones, (d ₃₎ fatty acids with aliphatic 1 Esters of valency alcohols, (d ₄ ) dialkyl carbonates, (e ₁ ) polyoxygenated C ₃ ~C ₆ alkanediols, (e ₂ ) polyoxidation An ester of a C ₃ -C ₆ alkanediol with at least one fatty acid, (e ₃ ) a polyoxy C ₃ -C ₆ alkanediol and an ether of at least one aliphatic monovalent alcohol, and (f ₁ ) a chain The group of alkanes, and any combination thereof, is selected. The absorbent article according to claim 1 or 2, wherein the amount of the blood modifying agent of the top sheet is larger than the amount of the blood modifying agent of the second sheet. The absorbent article according to claim 1 or 2, wherein the absorbent body further contains the blood modifying agent on the skin side. The absorbent article according to claim 1 or 2, wherein the liquid permeable top sheet and/or the second sheet is a nonwoven fabric or a woven fabric, and the blood modifying agent is adhered to the surface of the fiber of the nonwoven fabric or the woven fabric. The absorbent article according to claim 1 or 2, which is a sanitary napkin or a pad. The absorbent article according to claim 1 or 2, which is the second sheet between the liquid permeable top sheet, the absorbent body, the liquid impervious back sheet, the liquid permeable top sheet, and the absorbent body. The sheet-like absorbent article precursor is produced by spraying the blood modifying agent from the liquid-permeable top sheet side.